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Abstract 
 
Toxoplasma gondii is the causative agent of Toxoplasmosis in human and animals. T. gondii 
isolates are highly diverse. Hundreds of genotypes have been identified, but only three clonal 
lineages, namely Type I, II and III are prevalent worldwide. In mouse model, T. gondii strains 
can be divided into three groups based on their virulence, including the virulent (LD100=1), the 
intermediately virulent (LD50 = 10
3
-10
4
) and the non virulent (LD50 > 10
5
). The clonal Type I, II 
and III T. gondii strains belong to these three groups, respectively. Epidemiologic studies suggest 
the difference of virulence in mice may relate to the severity of toxoplasmosis in human 
infection. Therefore, it is necessary to understand biological differences in genetically different 
T. gondii strains and their effect on the host responses. To date, the majority of data published on 
this aspect has been limited to in vitro assays. Here, we used in vivo assays to investigate host 
responses upon infection of distinct Toxoplasma strains. 
 
Our studies examined host response to infection of the three widespread clonal lineages 
of T. gondii using a mouse model. The following results were revealed: (i) increased tissue 
burden in mice is the indicator of virulence of T. gondii. Quantification of parasite burden in the 
spleen of mice showed significantly more parasites for Type I strain than that of Type II and III 
strains, with the latter two having comparable parasite burdens. Given that the Type II strains are 
more virulent than the Type III strains in mice; this result suggests that difference in host 
response is the result of specific parasite-host interaction, which is not simply due to the 
difference of parasite tissue load. (ii) gene expression in the host is strongly influenced by 
parasite genetic background. Transcriptional profiles of mice infected with the above three types 
of T. gondii strains showed that the overall gene expression patterns are similar between Type I 
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and Type II infected mice and both stimulated stronger and more polarized change comparing to 
Type III strain. These results emphasize the importance of studying T. gondii pathogenesis in the 
host with the consideration of parasite genetic diversity. Such research could possibly aid in 
select appropriate regimes to treat toxoplasmosis caused by diverse T. gondii strains.   
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CHAPTER I. LITERATURE REVIEW 
 
Apicomplexa phylum 
 
 The Apicomplexa phylum is a large group of protozoan microorganisms. The name 
characterizes key features of these organisms to include a unique organelle apical complex 
structure. The apical complex structure aids in penetration of the organism into host cells. 
Members of this phylum have great biological and veterinary significance, such as Neospora, 
Hammondia, Plasmodium and Toxoplasma gondii. For example, Plasmodium- causative agent of 
malaria, Neospora- pathogen in cattle and dogs and Sarcocystis- pathogen in mammals and 
snakes.  
Toxoplasma gondii biological significance:  
  T. gondii is an obligate intracellular parasite that can infect any warm blooded 
vertebrate and birds. It is the only known species in the genus Toxoplasma and is considered one 
of the most successful eukaryotic pathogens in the world. T. gondii is the causative agent of 
toxoplasmosis.  It infects up to one third of the human population (Tenter AM, 2000). In 
immunocompromised individuals, infection can cause severe encephalitis, potentially leading to 
death in some cases. Acute infections in pregnant women can result in a condition known as 
congenital toxoplasmosis, in which symptoms could be blindness, mental retardation or even 
death of the fetus (Dubey, 2009). Healthy individuals are asymptomatic and can show limited flu 
like symptoms.  
T. gondii life cycle and transmission:  
 T. gondii has a complex life cycle (Figure 1-1.A) that includes both sexual and asexual 
replication. Cats serve as the definitive host where the parasite undergoes sexual replication. An 
infected cat can shed millions of oocysts into its feces, which can contaminate the environment.  
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In  general,  oocysts  have  been  defined  as  structures  consisting  of a  thick wall which contain 
replicative structures and are considered the infectious form of the organism facilitating 
transmission. More specifically, T. gondii oocysts contain developing sporozoites. The thick wall 
structure aids in survival in harsh environments and increased viability over extended periods of 
time. Transmission to intermediate host can then occur via ingestion of sporulated oocysts from 
contaminated food or water. Within intermediate host, asexual replication occurs. There are two 
distinct stages of T. gondii during asexual replication: the tachyzoite and bradyzoite forms 
(Figure 1-1.A-C). In the infected animal, tachyzoites may differentiate into bradyzoites and form 
tissue cysts. These cysts are found predominantly in the central nervous system and muscle 
tissue, where they may reside for the life of the host. The development of tissue cysts throughout 
the body defines the chronic stage of the asexual cycle. Cysts that are ingested through eating 
infected tissue are ruptured as they pass through the digestive tract, causing bradyzoite release. 
These bradyzoites can then infect the epithelial cells of the intestine, where they can differentiate 
back to tachyzoite stage for dissemination throughout the body, completing the asexual cycle 
(Black, 2000). When this occurs in the feline, the parasite can undergo sexual replication again.   
T. gondii stage conversion during asexual replication:  
The tachyzoite form is characterized by rapid replication within any nucleated cell of 
intermediate host and non intestinal epithelial cells of the definitive host (Ajioka, 2007). Invasion 
of host cells by tachyzoites occurs firstly by adhering to host cells via parasite microneme 
proteins.  Using the apical complex and its actin myosin cytoskeleton, the parasite actively 
penetrates the host cell without disruption or rearrangement of the host cell membrane (Sibley, 
2011). Once inside the cell, the parasite resides within a protective parasitophorus vacuole (PV),  
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Figure 1-1. A) Life Cycle of T. gondii. Illustration shows cat as the definitive host. Oocysts are 
shed in the environment and ingested by intermediate host (animals and humans). Tachyzoite 
form can be transmitted among intermediate host by vertical transmission. The cycle continues 
when cats eat cyst infected meat. B) Transmission electron micrograph of a mouse peritoneal 
macrophage containing several tachyzoites. C) Tissue cyst freed from mouse brain. Note the cyst 
wall (arrow) enclosing hundreds of bradyzoites. 
A 
C B 
Dubey 1998 
Ajioka and Soldati. 2007 
A 
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it follows a  lytic  lifestyle  and  undergoes  rapid  replication.  The host cell ruptures when it can 
no longer support the growth of tachyzoites. Inside the cell, tachyzoites will differentiate into 
bradyzoites (Lyons, 2002). Bradyzoites are the slower replicating dormant form of the parasite 
and is associated with the chronic infection. At this stage the parasite is protected from the host 
immune system. The bradyzoite is characterized by a thick tissue cyst wall that encases the 
replicating bradyzoites inside (Dubey, 1998; Parmley, 1994; Weiss, 2000). Tissue cysts can vary 
in size ranging from 5-8.5 x 1-3 μm (Mehlhorn, 1980). In vivo, the factors responsible for stage 
conversion have been poorly understood.  Limited data have shown certain environmental 
factors to play a role in promoting stage conversion in vitro to include change in pH, temperature 
and oxidative stress (Bohne, 1994; Soete, 1994, 1993). The ability to convert to the bradyzoite 
stage is advantageous for parasite survival inside the host.  This characteristic is strain specific 
and observed among intermediate and nonvirulent T. gondii strains and not virulent strains 
(Howe, 1996; Howe, 1995). Studies have shown that virulent Type I strains (ex. RH) are not able 
to establish chronic infection by conversion into bradyzoite latent form (Djurkovic-Djakovic, 
2005). Understanding this phenomenon is of great interest, as this could elucidate key virulence 
factors. 
Genetic diversity and virulence:  
T. gondii infects up to one third of the human population (Dubey, 2009). Toxoplasma is a 
widespread pathogen with isolates found worldwide. Due to the successful nature of 
Toxoplasma, isolates have been obtained from a broad host range including mammals and birds 
(Corad, 2005; Dubey, 2007; Dubey, 2008).  Previous dogma regarding genetic makeup of 
Toxoplasma gondii isolates have largely been classified into 3 distinct lineages as types (I, II, III) 
based on restriction fragment length polymorphism (RFLP) (Howe, 1995). Although this method 
 5 
is useful in the identification of genotypes, there are limitations based on the number of markers 
used. In North America and Europe, natural isolates of animals and humans can be readily 
grouped into Type I, II or III lineages, with Type II strains predominant in infection (Carme B, 
2002; Darde, 2004). Although the three lineages of T. gondii differ by only 1-2% (Howe, 1995) 
they display very unique virulence phenotypes (Boyle, 2006; Grigg ME, 2001). Virulence of T. 
gondii strains is usually assessed in mice. In general, Type I lineage is considered virulent in 
mice (LD100 =1 parasite), showing no survival at ~ 2 weeks. Type II lineage is considered 
intermediately virulent (LD50=10
3
 - 10
4
) and can have similar phenotype to Type I at high dose. 
Lastly, Type III is nonvirulent (LD50>10
5
) showing ~ 20% mortality at day 30 (Saeij, 2006; Su, 
2002). Data has revealed that there is an association with virulence in mice and disease in 
humans (Carme B, 2002). Carme et al, infected mice with T. gondii strains isolated from patients 
with severe toxoplasmosis and showed that these same strains were acutely virulent in mice 
(Carme B, 2002). Genome-wide QTL mapping revealed the loci responsible for acute virulence 
in 34 independent progeny generated from a genetic cross between the virulent type I strain GT-
1 and the nonvirulent type III strain CTG (Su, 2002). CD1 outbred mice were infected via 
intraperitoneal (I.P.) injection with the parental strains and their progeny.  QTL results identified 
Chromosome VIIa as loci controlling virulence traits such as mortality and serum responses. 
Further analysis revealed Rop18 as major factor controlling acute mortality (Taylor, 2006). 
When Type I Rop18 was transfected into Type III background, and inoculated into mice, 
increased mortality comparable to wild type I was observed.  This Rop18 is a member of a 
family of parasite proteins that are secreted from apical organelles called rhoptries (Bradley, 
2005). Due to this finding, interest on this family of proteins and their role in virulence has 
emerged.    
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Host response:  
Once inside the cell, the host elicits a series of responses to T. gondii infection. More 
commonly, the parasite induces a potent and long lasting protective immunity (Denkers, 1998; 
Jebbari, 1998; Yap, 1999). Although this protective immune response is efficient, it does not 
eliminate the parasite. Instead, the host and parasite achieve an equilibrium which allows for 
coexistence for the lifetime of the host. This equilibrium is compromised if the host has major 
defects in the immune system such as in AIDS and organ transplant patients. The Th1 immune 
response has been widely described as the mechanism responsible for maintaining this balance 
between host and parasite during infection. The Th1 immune response is characterized by 
increased levels of IL-12 and IFN-γ. The proinflammatory effects of these cytokines, including 
production of the microbial effects, nitric oxide, are eventually dampened by the anti-
inflammatory cytokine, IL-10, TGF-β and IL-27 (Miller, 2009). Interestingly, the over reaction 
of this same response is responsible for mortality of mice infected with virulent T. gondii strain 
but not the intermediate ones (Mordue, 2001). Taken together, such data shows the critical 
relationship between host- parasite interaction and its effect on clinical outcome. 
Macrophages, neutrophils and dendritic cells (DC) work together to elicit the immune responses 
necessary for host survival from T. gondii infection (Figure 1-2). Generally, dendritic cells play a 
role in presentation of antigen to T lymphocytes and control Th1 vs. Th2 differentiation. It has  
been suggested that the parasite can use the host immune system to facilitate spread during 
microbial infections (Denkers, 2004). During T. gondii infection, it was shown that the parasite 
has chemokine like activity which recruits immature dendritic cells (Diana, 2005). Data has 
suggested that when mice are infected with T. gondii, splenic DC undergo strong activation and 
produce  IL-12 (Straw, 2003).  DCs have also been  implicated  in playing a major role for IL-12  
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Figure 1-2. T. gondii subversion of immune system during natural infection. Toxoplasma 
gondii probably invades the mucosal intestinal epithelium of its host by infecting enterocytes (a), 
by penetrating through tight junctions (b), or by being sampled by DCs (c). When enterocytes are 
infected by the parasites, physiological and morphological disturbances occur, and the 
enterocytes can secrete cytotoxic molecules, such as NO (d). In addition, enterocytes respond to 
infection by secreting chemokines and cytokines that attract PMNs (e), MF (f) and DCs (g). 
When stimulated, these cells from the innate immune system can be directly microbiocidal. They 
also produce cytokines, such as IL-12, which trigger the adaptive CD4 immune response (h). To 
be elicited, a specific immune response requires the presentation of antigens, mainly through 
DCs. Activated T cells, in addition to NK and NKT cells (i) stimulated by cytokines produced by 
infected enterocytes, such as IL-15, secrete IFN-g that activates MF, DCs and enterocytes for 
parasite clearance. IEL (j) are cytotoxic for infected enterocytes and produce TGF-b, which 
might limit IFN-g production. Parasite replication in the intestine combined with inflammatory 
response development might lead to epithelial damage, giving the opportunity for commensal 
bacteria, including LPS-rich Gram-negative bacteria, to translocate beyond the epithelial layer 
(k). Toxoplasma gondii blocks numerous LPS-inducible cytokines (l) and cytokine-related genes 
in MF, infected in vitro as indicated by (l). Adapted from Gatel and Werts 2008. 
Buzoni- Gatel and Werts 2008 
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in protection (Fischer, 2000). Like DCs, neutrophils also play a major role during T. gondii 
infection. Commonly, neutrophils are characterized by there ability to respond and migrate to 
invading pathogens at the site of infection. Neutrophils take up T. gondii by phagocytosis and 
release free radicals to environment. Data has shown that during Toxoplasma infection in 
neutropenic mice, both Th1 and Th2 cytokines are lower. This decrease results in lethal systemic 
pathology associated with elevated parasite levels (Bliss, 2001; Miller, 2009). Interestingly, 
when impairing the ability of neutrophils to reach the site of infection (using CXCR2-/- or 
CCR1-/- knockout mice), impaired resistance and enhanced growth of T. gondii was observed 
(Del Rio, 2001; Khan, 2001). In general, macrophages are important phagocytic cells and play an 
essential role in detection and elimination of pathogens to include Toxoplasma. Along with 
neutrophils and DCs, macrophages are an important source of IL-12 production during early 
infection (Aliberti, 2005) (Figure 1.2). This production of IL-12 leads to downstream production 
of IFN-γ (Miller, 2009) which both are  hallmarks of the Th1 response, indicating an important 
role of macrophages in maintaining balance between host and parasite. Exposure to IFN-γ and 
TNF also activates macrophage mediated mechanisms that restrict intracellular replication and 
promote the process of autophagy. During autophagy, autophagosomes surround parts of the 
cytosol and organelles to fuse with lysosomes to form autolysosomes (Andrade, 2006). When 
parasites enter activated macrophages disruption of the PV occurs resulting in the 
autophagolysosomal elimination of the parasite (Yap, 2007). 
Taken together, we observe that there is an extremely important role of host response and its 
result on clinical outcome of disease persistence during T. gondii infection. Understanding this 
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host these host responses will continue to elucidate major players responsible for pathogenesis 
control.  
Observations That Led To Research 
Toxoplasma gondii is a successful pathogen, infecting up to one third of the human 
population. T. gondii is widespread and hundreds of genotypes have been identified worldwide. 
PCR-RFLP analysis of hundreds of isolates collected from a broad host range revealed that Type 
II strain was the most common lineage worldwide, followed by Type III strain. Surprisingly, 
highly virulent in mice, Type I strain, though widely distributed geographically, isolation 
frequency is limited.  
Genetic diversity among distinct T. gondii strains (Type I, II and III) has been shown to  
differ by ~ 1-2% at the DNA sequence level. Although genetically similar, they have very 
different phenotypes. Virulence, transmigration and growth rate are among these phenotypes that 
differ between strains. Results have shown that in vitro, Type I parasites have increased motility 
and ability to migrate when compared to Type II and III parasites (Barragan A, 2002). The 
correlation between T. gondii virulence and growth rate have been well characterized (Kaufman, 
1958; Kaufman He, 1959). It has been demonstrated that Type I parasite burden is higher 
compared to mice infected with intermediate Type II strain (Mordue, 2001). This was supported 
by Jerome et al. when he showed non virulent parasites growth rate decrease after ~ 20 divisions, 
while Type I continued to rapidly replicate. Interestingly, in this same study, a spontaneous 
mutation with high virulence arose from a non virulent strain of T. gondii and the mutant lost the 
ability to switch from fast to slow growth stage (Jerome, 1998). Taken together, it is reasonable 
to hypothesize that maintaining fast growth phase and the ability to reach a high parasite load in 
mice might be a common phenomenon for virulent strains. To test this hypothesis, in Chapter II 
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we developed an assay to determine mouse-virulence of Toxoplasma. Using quantitative PCR 
(qPCR) approach, we determined parasite burdens of experimentally infected CD-1 outbred 
mice. Our results showed that parasite concentrations in spleen tissues were higher in mice 
infected with virulent T. gondii strains than mice infected with intermediately and non-virulent 
strains. Results confirmed that indeed increased growth rate is the indicator of virulence. In 
addition, we offer an alternative method for determining virulence, rather than commonly used 
mortality assays, which can be harsh procedures and costly.  
 My work presented in Chapter II laid the framework for analysis of understanding the 
biological differences in host response to T. gondii of different genetic backgrounds (Chapter 
III). Although virulence of T. gondii is different among strains, the host plays an important role 
in resistance to infection.  Mordue et al., using limited reference strains from the clonal Type I 
and II lineages, showed that acute virulence was associated with an over stimulation of Th1 
immune response by the Type I virulent strain which eventually kill the mice (Barragan A, 2002; 
Denkers, 2001; Mordue, 2001) suggesting immune pathology may play an important role in 
mortality.  
 Understanding host response to T. gondii has been limited to in vitro methods. Although, 
increased knowledge has been obtained from these studies, conclusions are limited. To overcome 
these limitations, in Chapter III, we use an in vivo mouse model to study host response to T. 
gondii infection. This is of relevance to human toxoplasmosis, as mouse-virulent T. gondii 
strains may potentially be associated with severe acquired toxoplasmosis in immunocompetent 
patients (Carme B, 2002). Using three major genotypes of T. gondii, we show that parasite 
genetic background plays an important role in host response to infection.  
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CHAPTER II. INCREASED PARASITE LOAD OF TOXOPLASMA GONDII IS THE 
INDICATOR OF ACUTE VIRULENCE IN MICE 
 
This chapter has been submitted for publication as a regular article for Veterinary Parasitology. 
Rachel D. Hill and Chunlei Su*, Department of Microbiology, University of Tennessee, 
Knoxville, Tennessee 37996-0845. *Corresponding Author.  
 
Introduction 
 Toxoplasma gondii is found worldwide and infects up to one third of human population. 
In general, T. gondii strains are highly diverse and hundreds of genotypes have been identified 
worldwide. In mice, T. gondii isolates are essentially divided into two groups: the virulent and 
the relatively less virulent, regardless of their genotypes. The clonal Type I lineage is an example 
of virulent parasite (LD100=1 parasite), whereas the clonal Type II and III lineages are the 
relatively less virulent parasites that can be further divided into intermediately virulent (Type II, 
LD50=10
3
 - 10
4
) and non-virulent (Type III, LD50>10
5
) strains, respectively (Saeij, 2006; Sibley, 
1992b; Su, 2002) 
Previous studies among limited strains have shown that virulent strains have higher 
parasite loads, which leads to an overproduction of Th1 cytokines (Gavrilescu, 2001; Mordue, 
2001). Saeij et al. also characterized differences among virulent and less virulent strains in mice. 
Their results showed that the virulent strain demonstrated increased parasite burden than the less 
virulent strain throughout the course of infection in mice (Saeij, 2004). Also, studies have shown 
that the virulent strain was less capable of switching from the faster growth phase of tachyzoite, 
to the slow growth phase of bradyzoite (Jerome, 1998; Radke, 2006). Taken together, the data 
suggests that maintaining fast growth phase and the ability to reach a high parasite load in mice 
might be a common phenomenon for virulent strains. This trait may be explored to develop assay 
to determine mouse-virulence of Toxoplasma. In this study, we took the quantitative PCR 
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(qPCR) approach, and determined parasite burdens of experimentally infected CD-1 outbred 
mice with 19 T. gondii isolates, in which the virulence phenotypes have been determined 
previously by mortality assay in mice. Our results showed that parasite concentrations in spleen 
tissues were two orders of magnitude higher in mice infected with virulent T. gondii strains than 
that infected with intermediately and non-virulent strains at day 7 post infections. The results 
confirmed that acute virulence indeed can be inferred by tissue burden of infected mice.  
 Materials and Methods  
Cell culture and parasite strains. Human foreskin fibroblasts (HFF) were grown in Dulbecco‟s 
modified Eagle medium (DMEM) supplemented with 10% of heat inactivated fetal bovine serum 
(Hyclone #SH30070.03 HI/IR), 1% of 100X Non Essential Amino Acids (NEAA-Fisher 
Scientific cat. no. - SH3023801), 4 mM Hepes buffer and 10 µg/ml gentamicin (Invitrogen 
#15710-64) and maintained in T25 vented culture flasks at 37°C with 5% CO2..  T. gondii strains 
were expanded and maintained in confluent HFF monolayer to reach consistent two-day 
passages prior to use for experiment. Two groups of parasites were used in this study. Group 1 
includes virulent Type I strain GT1, non-virulent Type III strain CTG and nine progeny from 
genetic crosses of GT1 and CTG strains,  including A9SF and G2AF (non-virulent progeny), 
A6AF, C285-11, C285-1 and C285-4 (intermediately virulent progeny), and C285-13, C295-3 
and C295-31 (virulent progeny) (Khan, 2005; Su, 2002). These progeny were selected to 
represent virulent, intermediately virulent and non-virulent phenotypes based on mortality assays 
(Khan, 2005; Su, 2002). Group 2 parasites include 10 natural isolates from a variety of hosts 
with five (RH, GT1, VEL, MAS and CAST) being acutely virulent, three intermediate (PTG, 
DEG and COUGAR) and two non-virulent (STRL and CTG) strains in mice (Khan, 2007; 
Sibley, 1992b; Su, 2003). Genotypic characterizations of group 2 strains are listed in Table 2.1.  
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In vivo parasite load determination by qPCR. Two experiments were performed to determine 
in vivo parasite load in the spleen of the infected female outbred CD-1 mice (Harlan Sprague). In 
the first experiment, virulent strain GT1, non-virulent strain CTG and the 9 recombinant clones 
of GT1 X CTG cross were tested in mice.  T. gondii tachyzoites were grown in HFF cell culture, 
harvested and filtered through 3 μm pore size polycarbonate filters (Nucleopore Corp, 
Pleasanton, CA). Two hundred tachyzoites were inoculated by intraperitoneal injection (IP) into 
four 8-week old CD-1 mice.  At days 3, 5 and 7 post infections, spleens were collected, weighed, 
homogenized in 5 ml PBS and diluted to 0.02g/ml in PBS.  For qPCR standard controls, the 
spleen of a non-infected mouse was homogenized and diluted to the above concentration in PBS 
and T. gondii tachyzoites were spiked into the homogenized spleen to make a series 
concentrations of 1x10
7 
to 1x10
3 
parasites/ml.  Aliquots of 500 µl homogenized spleens were 
mixed with 500 µl PBS and 50 µl of 10 mg/ml proteinase K, incubated at 55 °C for 2 hours. 
DNA was extracted using Qiagen DNeasy Blood and Tissue Kit (Qiagen cat no. 69504). The 
number of parasites in mouse spleen was determined by qPCR of extracted DNA using a 
TaqMan probe targeting the ITS1 sequence (GenBank Accession# AY143141).   The primers for 
PCR amplification were ITS1-Fx: GAAGGGGCTCAATTTCTGG and ITS1-Rx: 
TGTTCCTCAGATTTGTTGTTTGA, which amplifies a 117 bp sequence. The ITS1 probe was 
5‟-/56-FAM/CGTGTCTCTGTTGGGATACTGATTTCCAGG/3BHQ-1/-3‟, with the 5‟ end 
labeled with FAM and the 3‟ end labeled with Black Hole Quencher-1 (BHQ-1) (Integrated 
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Table 2-1. Genotyping characterization of natural isolates of T. gondii 
       Marker        
Strains Hosts & 
Locations 
SAG1 SAG2
*
 SAG2
†
 SAG3 BTUB GRA6 c22-8 c29-2 L358 PK1 Apico Lineages Virulence 
in mice
 ‡
 
RH Human 
USA 
I I I I I I I I I I I Type I Vir 
GT1 Goat 
USA 
I I I I I I I I I I I Type I Vir 
VEL Human 
USA 
I I I I I I I I I I I Type I Vir 
PTG Sheep 
USA 
II II II II II II II II II II II Type II INT 
DEG Human 
France 
II II II II II II II II II II I Type II 
variant 
INT 
CTG Cat 
USA 
II III III III III III III III III III III Type III Non 
STRL Human  
USA 
II III III III III III III III III III III Type III Non 
CAST Human  
USA 
I I I I I I II I III I III Atypical Vir 
Cougar Cougar  
Canada 
I II II III II II II u-1 I u-2 I Atypical INT 
MAS Human 
France 
u-1 I II III III III u-1 I I III I Atypical Vir 
*
 Typing at SAG2 locus by the method of (Howe, 1997)  
†
 Typing at 5‟ end of SAG2 locus by the method of (Su, 2006).  
‡„Virulent‟ (Vir) is defined to T. gondii isolates with LD100 equal to 1 viable parasite, intermediately virulent (INT) with LD50 equal to 10
3
-10
4
 parasites, 
and non-virulent (Non)  isolates with LD50>10
4
 (Sibley, 1992; Su, 2002) 
The u-1, u-2 are alleles different from that of the clonal Type I, II and III lineages. 
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DNA technologies, INC). qPCR had a total reaction volume of 25 μl containing 16.24 μl of 
ddH20, 2 μl of 10X PCR buffer, 2 μl of 2.5mM dNTPs, 2 μl of 25mM MgCl, .5 μl of 10 mg/ ml 
BSA, 1.3 μl 50 μM ITS1-Fx and ITS1-Rx primers, 0.2 μl of 50 μM ITS1 probe and 0.3 μl of 5 
U/μl Faststart Taq DNA polymerase (Roche Applied Science, Indianapolis, IN). One microliter 
of purified DNA was added as template and PCR reaction mix was transferred to 25 μl Cepheid 
PCR tubes. The reaction was carried out using a Smart Cycler (v2.0b, Cepheid, Sunnyvale, CA) 
with the following conditions: 94ºC for 60 sec, then 45 cycles of 92ºC for 15 sec, 52ºC for 30 sec 
and 72ºC for 40 sec. The Ct value for each sample was compared to the standard controls (10
7 
to 
10
3
 parasites/ml and the negative) to estimate the concentration of parasite per gram of spleen.  
In the second experiment, in vivo parasite load was determined for 10 natural isolates, 
including the five virulent T. gondii strains (GT1, RH88, VEL, MAS and CAST) and three 
intermediately (PTG, DEG and COUGAR) and two non-virulent (CTG, and STRL) strains. 
Parasites were grown in HFF cell culture and the tachyzoites were harvested as described above. 
Two hundred tachyzoites were inoculated into 4 mice for each parasite strain. At day 7 post 
infection, the mice were euthanized and the spleens were collected, weighed and homogenized. 
Genomic DNA extraction and qPCR was performed as above to determine parasite load in 
spleen tissue.  
Competition assay. Toxoplasma gondii tachyzoites of Type I (GT1), Type II (PTG) and Type 
III (CTG) strains were prepared in HFF cell culture and harvested as the method described 
above. Two hundred tachyzoites of GT1 were mixed with 800 tachyzoites of PTG or CTG (1:5 
ratio) and IP injected into four female outbred CD-1 mice. For positive controls, two mice were 
infected with 200 tachyzoites of GT1 strain, and two mice with 800 tachyzoites of CTG strain. 
At days 5 and 7 post infection, mice were euthanized and spleens were collected, weighed and 
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homogenized.  Parasite numbers for all samples was determined by qPCR as described above. In 
a separate experiment, a 1:1 ratio of GT1: PTG, a 1:1 ratio of PTG: CTG (mixture of 200 
tachyzoites of each strain), and a 1:5 ratio of GT1: PTG (200:800 tachyzoites) were also tested in 
mice by IP injection. For controls, two mice were infected with 200 tachyzoites each of the GT1, 
PTG and CTG strains.  On day 7 post infection, mice were euthanized, and genomic DNA was 
extracted from the spleen. Parasite numbers for all samples was determined by qPCR as 
described above.  
RFLP analysis. To determine the parasite types for the competition assay, a 546 bp fragment of 
the SAG2 gene was amplified by nested PCR and then treated with restriction enzymes HinfI 
and TaqI by the method described previously (Su, 2010) 
Data analysis. Parasite numbers were determined by comparison to a standard curve generated 
by linear regression analysis of Log10 (number of parasites per gram of the spleen) versus FAM 
Ct values for each run of qPCR. Differences of parasite dissemination in vivo were analyzed by 
simple ANOVA using an F-test (Minitab v12, State College, PA).   
Results  
Establishment of qPCR approach as method for quantifying parasite tissue burden. 
The qPCR was run for 45 cycles to quantify tissue burden of infected mice.  qPCR output 
was calculated based on threshold cycle (CT). CT is defined as the PCR cycle at which the 
fluorescent dye becomes exponential in amplification. Therefore the lower the Ct, the greater the 
amount of DNA copy numbers (Schmittgen, 2008). We generated a standard curve using known 
concentrations of T. gondii to calculate absolute number of Toxoplasma DNA. A representative 
example of qPCR results were presented in Fig. 2.1. The R
2
 of linear regression for all qPCR  
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Figure 2-1. Example of qPCR output. The parasite loads were determined using DNA samples 
extracted from the spleen of infected mice. The qPCR was run for 45 cycles. The X axis 
indicates the number of PCR cycles, Y axis shows fluorescent signal of reporter dye. The 
threshold was set at 30.  A standard curve was generated to measure parasite concentrations in 
experimental samples. In this example, the standard curve equation is Y = -0.219X + 12.697 and 
R2 = 0.99. Labeled in this figure are a few representative curves of standards and samples. ND 
indicates DNA not detectable.  
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standard curves were greater than 0.98, indicating the estimation of parasite load was acute by 
this approach.  
Virulent strains have increased tissue burden compared to intermediate and non virulent strains. 
Parasite  loads  in  the  spleen  at  days  3,  5 and  7  post-infection  for  GT1 and CTG  
(parental strains), A9SF and G2AF (non-virulent progeny), A6AF, C285-11, C285-1 and C285-4 
(intermediately virulent progeny), C285-13, C295-3 and C295-31 (virulent progeny) are 
summarized in Fig. 2-2.  Individual clones are shown in panels A and B, and the average parasite 
load per group in panel C. At day 3 post IP, the in vivo parasite load was low and could not be 
reliably detected by qPCR.  At day 5 post IP, the average Log10 (parasites/g spleen) were 5.9, 5.1 
and 5.1 for virulent, intermediately virulent and non virulent clones, respectively, the difference 
is not statistically significant (P>0.05). At day 7 post IP, the average Log10 (parasites/g spleen) 
were 7.4, 5.7 and 5.6 for virulent, intermediately virulent and non-virulent clones, respectively. 
The virulent clones reached significantly higher concentration compared to intermediately 
virulent and non-virulent clones (P ≤ 0.05).  On average, there are about 30 times more parasites 
on day 7 than that on day 5 for virulent clones. However, parasite loads only increased slightly 
for intermediately and non-virulent clones on day 7.  At day 7, there are about 50 times more 
parasites in virulent clones than that of intermediately and non-virulent clones. No difference 
was observed between intermediately and non-virulent clones at both day 5 and day 7 (Figure. 2-
2). 
Parasite loads in the spleen tissues at day 7 post IP for natural isolates of five virulent, three 
intermediately virulent and two non-virulent strains are summarized in Figure. 2-3. The averages 
Log10 (parasites/g spleen) for GT1, RH88, VEL, MAS and CAST were 7.9, 7.4, 8.5, 8.6 and 7.1,  
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Figure 2-2. Parasite burdens in the spleens of mice. A. Day 5 post infection. Dotted bars are 
for non-virulent strains, hatched bars are for intermediately virulent strains, and open bars are for 
virulent strains. B. Day 7 post infection. On average, virulent strains have significantly high 
parasite numbers by days post infection. C. Changes in parasite load over time. Solid line is for 
acutely virulent strains, dotted line is for intermediately virulent and dashed line is for non 
virulent.  
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Figure 2-3. Parasite burdens Log (parasites/g spleen) in mice indicated by mean and standard 
deviation at day 7 post IP .  A. Parasite load in the spleen tissues for 10 natural isolates, including 
GT1, RH, VEL, MAS and CAST  (known virulent strains, open bars), PTG, DEG, COUGAR, 
CTG and STRL are intermediately virulent and non-virulent strains (hatched bars). B. Average 
tissue burden (mean, standard error) for virulent versus non-virulent and intermediately virulent 
strains. 
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respectively (Figure. 2-3.A). The average Log10 (parasites/g spleen) for intermediately virulent 
strains PTG, DEG, COUGAR, and non-virulent strains CTG and STRL were 5.9, 5.2, 4.9, 5.4 
and 5.1, respectively (Figure. 2-3.A). Since parasite loads for intermediate and non- virulent 
strains were similar, they were combined to compare to the virulent strains. On average, the 
virulent strain  parasite  loads  were  more  than  two orders of magnitude higher (>100 times) 
than that of 
 intermediate and non-virulent strains, P<0.0001 (Figure. 2-3.B). Comparing the isolate CAST 
that had the lowest parasite load within virulent strains with the isolate PTG that had the highest 
parasite load within the non-virulent strains, CAST still had 15 times more parasites than PTG, 
and the difference is significant (P=0.02, two-sample t-test) (Figure. 2-3.A).  
Virulent T. gondii strain outgrows intermediate and non virulent strains during mixed infections.  
qPCR was performed to quantify parasite concentration in the spleens of mice infected with 
tachyzoites mixture of GT1: CTG at 1:5 ratio (200:800 tachyzoites) (Figure. 2-4. A). On day 5 
post IP, the Log (parasites/g spleen) was 6.8 (s.d. = 0.34) which was comparable to GT1 control 
(7.9, s.d=0.4); this was more than 10 times higher than CTG (6.5, s.d. =0.2). On day 7 post IP, 
the Log (parasites/g spleen) was 8.8 (s.d. =0.3) for GT1: CTG mixture, comparable to GT1 
control (9.0, s. d. =0.7), this was about 80 times higher than the CTG control (6.6, s.d. = 0.4) 
(Figure 2-4.A). For the mixed infection and GT1 control, there were about 10 times more 
parasites at day 7 than that at day 5. For CTG control, the parasite loads were comparable 
between days 5 and 7 (Figure 2-4.A). 
RFLP Analysis at SAG2 locus showed that at day 5 the parasite was not reliably detected 
(Figure. 2-4. B). SAG2 was not detectable for mice infected with CTG (M1, M2), and a mouse 
infected with 1:5 of GT1: CTG (M4). One mouse infected with 1:5 of GT1:CTG (M1) showed a 
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mixed infection of both Type I and III alleles with comparable intensity. Type I allele of SAG2 
marker was observed for mice infected with GT1 strain (M1, M2) and a mouse with 1:5 of GT1: 
CTG infection (M2).   
At day 7, all mice infected with 1:5 of GT1: CTG mix showed the Type I allele. The mice 
infected with GT1 and CTG controls showed the expected Type I and III genotypes, respectively 
(Figure. 2-4.B).   
In a second competition assay experiment, qPCR was performed to quantify parasite 
concentration in the spleens infected with mixture of GT1: PTG at 1:1 ratio (200 tachyzoites 
each strain), mixture of GT1: PTG at 1:5 ratio (200:800 tachyzoites), and mixture of PTG: CTG 
at 1:1 ratio (200 tachyzoites each strain). On day 7 post IP, the Log (parasites/g spleen) for GT1: 
PTG (1:1 ratio) and GT1: PTG (1:5 ratio) were 7.6 (s.d. = 0.7) and 7.6 (s.d. = 0.2), respectively, 
which was comparable to GT1 control (7.8, s.d. = 0.8) (Fig 2-5.A). This is 20 times higher than 
PTG control (5.8, s.d. = 0.1). Also, on day 7 post IP, the Log (parasites/g spleen) was 5.6 (s.d. 
=0.6) for PTG: CTG mixture (1:1 ratio), comparable to PTG and CTG controls (5.8, s.d= 0.1 and 
5.1, s.d. = 0.4). There was no statistical significant difference in parasite concentration compared 
to non-virulent controls (Figure 2-5.A).  
RFLP analysis at the SAG2 locus revealed that mice infected with different ratios of Type I 
and II mixtures (1:1 or 1:5 of GT1: PTG), only revealed the Type I allele (Figure. 2-5.B). The 
1:1 mixture PTG:CTG showed a Type II allele in one mouse (M4), a Type III allele in one 
mouse (M3), and mixed alleles of Type II and III in two mice (M1 and M2) (Figure. 2-5. B). The 
mice infected with GT1, PTG and CTG as controls showed the expected Type I, II and III 
genotypes, respectively (Figure. 2-5.B). 
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Figure 2-4. Competition assay. A. Parasite burdens Log (parasites/g spleen) in mice at days 5 
and 7 post IP (mean, s.d.).  GT1 and CTG are positive controls of Types I and III, respectively. 
GT1 (200 tachyzoites) and CTG (800 tachyzoites) were mixed to give 1:5 ratio. Parasite load 
was determined by qPCR. B. Genotyping T. gondii in the spleen tissues of mice infected with T. 
gondii.  Marker SAG2 was amplified by nested PCR and then digested by restriction enzyme 
HinfI. The references RH, PTG and CTG represent Type I, II and III lineages respectively. M1, 
M2, M3 and M4 are the samples taken from infected mice. Competition assay was performed in 
four mice by infecting a 1:5 mixture of GT1 and CTG. Ctl is negative control in which no DNA 
template was used for PCR amplification. MK is DNA sample loading marker. nd, parasites 
were not detectable by PCR at the SAG2 locus.  
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Figure 2-5. Competition assay in mice at day 7 post IP (mean, sd).  A. GT1, PTG and CTG 
are positive controls of Types I, II and III, respectively. GT1 (200 tachyzoites) and PTG (200 
tachyzoites) were mixed to give 1:1 ratio. GT1 (200 tachyzoites) and PTG (800 tachyzoites) 
were mixed to give 1:5 ratio. PTG (200 tachyzoites) and CTG (200 tachyzoites) were mixed to 
give 1:1 ratio. Parasite load was determined via qPCR.  B. Genotyping T. gondii in the spleen 
tissues of mice.  Marker SAG2 was amplified by nested PCR and then double-digested by 
restriction enzymes HinfI and TaqI. Competition assay was performed in four mice (M1 to M4) 
in each treatment. Ctl is negative control in which no DNA template was added for PCR 
amplification. MK is DNA sample loading marker.  
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Discussion  
In this investigation we used an in vivo model to study the differences in parasite load in 
mice among distinct T. gondii strains. Our data suggested that virulent strains grow faster and 
reach a higher parasite load in mice than that of intermediately and non-virulent strains. This  
phenomenon is not strain specific but a general characteristic in all virulent strains tested in this 
study (Figure. 2-3, 2-4 and 2-5). Early studies suggested that virulent strains multiply more 
rapidly (Kaufman, 1958). This is consistent with in vitro growth data that showed Type I (RH 
and GT1) strains had increase levels of parasite growth (~70 parasites per vacuole) compared to 
Type II (Me49) and Type III (VEG) which had ~30 and ~25 parasites per vacuole, respectively 
(Radke, 2006). This finding can be explained by the ability of intermediately and non-virulent 
strains to convert to slow growing bradyzoite form, whereas virulent Type I strains is unable to 
make this conversion leading to subsequent uncontrolled growth.  
High parasite load of virulent T. gondii strains in host tissue would suggest that virulent 
strains outgrow intermediately and non-virulent strains in mixed infection. This was confirmed 
by competition assay and RFLP analysis (Figure. 2-4, 2-5). Together our data demonstrated that 
regardless of the ratio in mixed infection, virulent GT1 is consistently dominant over its 
intermediately and non-virulent counterparts, PTG and CTG, respectively. Genotypic patterns of 
(GT1:CTG) infection also corresponded to GT1 controls which further suggests that the GT1 
strain had taken over the culture and was now the dominant strain.  
RFLP analysis confirmed that intermediately and non-virulent strains have a slower growth 
rate and have low tissue burden than virulent strains. Mice infected with PTG: CTG (1:1) 
showed mixed alleles of both PTG and CTG at day 7 post infection. These results suggest that 
both intermediately and non-virulent strains have comparable levels of parasite present.   When a 
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1:20 of GT1:CTG mixture was infected IP to two mice and followed by genotyping at day 9 post 
IP, only the allele of GT1 strain was observed (data not shown), confirming the finding that the 
virulent strains replicate faster than the intermediately and non-virulent ones.  
Previous study reported that, the MS-J strain, a spontaneous  mutant from Type III strain 
VEG  had increased growth rate and 100% mortality in mice compared to VEG tachyzoites 
whose growth shifted to bradyzoite (Jerome, 1998).  Data has also shown that Type I virulent 
(RH) strain completely lyse cells much faster than Type II and III strains in vitro (Saeij, 2005). 
Together, these results prove that there is a correlation between increased growth rate and 
virulence. There may be regulatory or genetic elements that are suppressing virulence in 
intermediately and non-virulent T. gondii strains.  
In this chapter, we confirmed that increased growth of parasite in mice is a common feature 
of virulent strains regardless of their genetic background. This assay only needs 7 days compared 
to 20-30 days for mortality assay. The parasite tissue load assay is advantageous over 
conventional mortality assay considering the length of time needed and minimum stress on 
experimental mice. The limitation of this assay is that it can not distinguish parasite strains of 
intermediately virulent from non-virulent strains. In summary, parasite loads in spleen tissues of 
infected mice can be used as an alternative assay to determine acute virulence of T. gondii in 
mice.  
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Introduction 
 Toxoplasma gondii is the causative agent for toxoplasmosis. T. gondii infects almost all 
warm blooded vertebrates and birds. It infects up to one third of the human population (Dubey, 
2009). In immunocompromised individuals, infection can cause severe encephalitis. Acute 
infections in pregnant women can result in a condition known as congenital toxoplasmosis in 
which symptoms could be blindness, mental retardation or even death of the fetus (Joynson, 
2001).  
In North America and Europe, natural isolates of animals and humans are divided into the 
Type I, II and III lineages, with Type II strains predominant in infections (Darde, 2004; Howe, 
1995). In mice, the Type I lineage is highly virulent (LD100=1 parasite), whereas the Type II is 
intermediately virulent (LD50=10
3
 - 10
4
) and the Type III is non-virulent (LD50>10
5
) (Saeij, 
2006; Sibley, 1992a). Using reference strains from the clonal Type I and II lineages, it was 
shown that acute virulence was associated with rapid parasite dissemination, high parasite load 
and an over stimulation of Th1 immune response by the Type I virulent strain which eventually 
kill the mice (Barragan A, 2002; Denkers, 2001; Mordue, 2001) suggesting immune pathology 
may play an important role in mortality.  
Gene expression in the host infected with T. gondii has been characterized in vitro. In 
vitro gene expression analysis of macrophages infected with Type I, II or III strains revealed that 
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Type I infections elicited a stronger immune response compared to its non virulent counterparts 
(Lee, 2007). Work has shown that Type II ME49 can induce translocation of NF- κB to nucleus 
but not Type I RH in mice splenocytes and mice bone marrow derived macrophages (Dobbin, 
2002; Robben, 2004).The nuclear factor- κB (NF- κB) is known to have a critical role in 
regulating inflammatory immune and anti apoptotic responses during infection. Robben et al also 
showed that Type II induced increased levels of IL-12p40 but not Type I and Type III in a 
myeloid differentiation primary response gene 88 (MyD88) dependent and TLR2/TLR4 
independent manner in vitro (Robben, 2004). Altogether, this data indicates that parasite genetic 
background is important in inducing host gene expression. 
Commonly, in vitro methods have been used to characterize host parasite interaction 
during T. gondii infection. Host response to infection has been characterized in macrophage and 
other immune cells (Lee, 2007; Pollard AM, 2009). Although knowledge has been gained from 
these studies, conclusions are limited based on the controlled conditions characteristic of in vitro 
systems. It is unknown how these data will translate to in vivo scenarios. To overcome these 
limitations, we used an in vivo mouse model to study host response to T. gondii infection. This is 
of relevance to human toxoplasmosis, as mouse-virulent T. gondii strains may potentially be 
associated with severe acquired toxoplasmosis in immunocompetent patients (Carme B, 2002). 
Here we revealed the differences in gene expression in mice infected with three major genotypes 
of T. gondii. 
Materials and Methods 
  Cell culture of parasite strains and infection in mice. Human foreskin fibroblasts 
(HFF) were grown in Dulbecco‟s modified Eagle medium (DMEM) supplemented with 10% of 
heat inactivated fetal bovine serum (Hyclone#SH30070.03 HI/IR), 1% of 100x Non Essential 
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Amino Acids (NEAA-Fisher Scientific cat. no. - SH3023801), 0.4% of 1M HEPES buffer and 
0.1 % of 10 mg/ml gentamicin (Invitrogen #15710-64) and maintained in T25 vented culture 
flasks at 37°C with 5% CO2. T. gondii strains GT1 (virulent), PTG (intermediately virulent) and 
CTG (non-virulent) were expanded and maintained in confluent HFF monolayer to reach 
consistent two-day passages prior to use for experiments.  
Toxoplasma gondii tachyzoites of GT1, PTG and CTG strains were harvested by filtering 
through 3 μm pore size polycarbonate filters (Whatman cat. no. 420400) and counted. Five 
hundred tachyzoites of each of the GT1, PTG and CTG strains were inoculated into four 6-8 
week old female outbred CD-1 (ICR- Harlan Sprague) mice by intraperitoneal injection (IP). At 
day 5 post infection, mice were anesthetized to the state of unconsciousness, followed by 
euthanization with cervical dislocation. Five mL of ice cold PBS was injected into peritoneal 
cavity and then peritoneal lavage was collected. Cells of peritoneal lavage were pelleted by 
centrifugation. Supernatant was removed and pellet was resuspended in 1ml RNAlater, mixed 
and incubated in 4ºC for 1 hour, then stored in -70ºC until RNA extraction for microarray 
experiments. The spleens were collected from mice, weighed, homogenized and diluted in PBS 
to determine parasite load by real-time PCR (RT-PCR). 
 Microarray analysis. Total RNA was extracted from cells collected from peritoneal 
lavage of mice infected with GT1, PTG and CTG using Qiagen RNeasy Plus Mini Kit (Qiagen 
cat. no. 98 74131) following manufacturer‟s instruction. For host gene expression profiling, 
Affymetrix Mouse 1.0 ST array containing 266,220 full length mRNA was used. Microarray was 
carried out at the University of Tennessee Affymetrix Core Facility. RNA samples were 
processed according to the Affymetrix Protocol for One-Cycle DNA Synthesis using a Message 
Amp II102 Biotin Enhanced Kit (Ambion PN#am1791, Austin, TX). 5 μg of fragmented cRNA 
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was hybridized to the GeneChip, previously described. Arrays were washed and stained using 
the Affymetrix Hyb/Stain kit PN900720 and Affymetrix prepared wash solutions and an 
Affymetrix Fluidics 450 wash station. Arrays were immediately scanned using the Affymetrix 
7G scanner. Array images were visually inspected for anomalies. The individual chip scans were 
quality checked for the presence of control genes and background signal values. 
 Data normalization and statistical analysis. The raw data from Affycore Analysis was 
extracted and normalized with Robust Multichip Algorithm (GC RMA) using Partek® Genomics 
SuiteTM software. A two way analysis of variance (ANOVA) was used to detect genes with 
statistically significant expression levels between each T. gondii infection compared to untreated 
infection samples. Gene transcripts were considered to be differentially expressed when there 
was at least 2 fold changes in either direction, and the ANOVA p-value is less than or equal to 
0.05. 
 Microarray validation via RT-PCR. RNA from samples used for microarray analysis 
were used to quantify mRNA transcript levels of genes at the end of highly induced and the end 
of highly repressed in mice based on fold change signal intensity values (see TABLE 3-3). RNA 
was synthesized into cDNA via reverse transcription according to protocol using 
DyNAmo™SYBR® Green 2 Step qRT-PCR kit (New England Biolabs). In brief, RNA 
concentrations among infections were normalized (max 1 μg) and added to reverse transcription 
reaction for a total volume of 20 μl containing 10 μl of 2xRT buffer, 1 μl of 300 ng/μl random 
hexamer primers, 2 μl MULv reverse transcriptase and RNase free water. The reaction was 
carried out using the Eppendorf Mastercycler (Fisher Scientific). mRNA transcript levels were 
then quantitated by RT-PCR of cDNA. RT-PCR reaction had a total volume of 20 μl containing 
8.6 μl of H2O, 10 μl of 2X master mix (containing modified TbrDNA polymerase), 0.2 μl of 50 
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Table 3-1. Primer Sequence for quantitative RT-PCR 
 
a
 From the NCBI protein database 
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μm each of the forward and reverse primers (TABLE 3-1). The reaction was carried out using a 
Smart Cycler (v2.0b, Cepheid, Sunnyvale, CA) with the following conditions: 95°C for 15 min, 
(94°C for 10 sec, 55°C for 30 sec, 72°C for 30 sec) for 40 cycles. The addition of melting curve 
step was added as control for PCR product efficiency at 72-95°C. Relative quantification was 
used to determine the ratio between the quantity of the target normalized to GAPDH (NCBI 
accession no. NM_008084) reference gene using 2
-ΔΔC(t)
 method (Schmittgen, 2008). 
 Data mining. Gene functional analysis was conducted for differentially expressed genes 
using the Onto-Express (OE) annotation database. The input into OE was a list of gene symbols 
corresponding to differentially expressed genes for each treatment compared to untreated 
samples. The output was the functional category assigned to each gene based on specific 
experimental evidence or by theoretical inference (Draghici, 2003). For visual representation, 
fold change signal intensity values were natural log transformed and values for each gene were 
plotted. For each functional category of genes, statistical analysis were performed to compare 
mean fold changes of gene expression in mice infected with the Type I, II and III strains. The 
formula we used is: Mean = (Σ|x|/n), where x is the natural log of fold change/negative control. 
The |x| is used to remove the negative sign when genes are down-regulated. Standard deviation is 
also calculated for each mean value. 
 In vivo parasite load determination by RT-PCR. For RT-PCR standard controls, the 
spleen of a non-infected mouse was homogenized and diluted in PBS and T. gondii tachyzoites 
were spiked into the homogenized spleen to make a series concentrations of 1x10
7
 to 1x10
3
 
parasites/ml. All homogenized spleen samples were adjusted to a volume of 0.02 g/ml in PBS. 
Aliquots (500 ul) of homogenized spleens were stored in -20°C until use. To extract DNA from 
homogenized spleen samples, 500 ul PBS was added to 500 μl of the spleen lysate and samples 
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were digested by adding 50 μl of 10 mg/ml proteinase K and incubated at 55°C for 2 hours. 
DNA was extracted using Qiagen DNeasy Blood and Tissue Kit. The number of parasites in 
mouse spleen was estimated by RT-PCR of extracted DNA using a TaqMan probe targeting the 
ITS1 sequence (GenBank Accession# AY143141). The primers for PCR amplification were 
ITS1-Fx: GAAGGGGCTCAATTTCTGG and ITS1-Rx: TGTTCCTCAGATTTGTTGTTTGA, 
which amplify a 117 bp sequence. The ITS1 probe was 5‟-/56 
FAM/CGTGTCTCTGTTGGGATACTGATTTCCAGG/3BHQ-1/-3‟, with the 5‟ end labeled 
with FAM and the 3‟ end labeled with Black Hole Quencher-1(BHQ-1) (Integrated DNA 
Technologies, Inc.). RT-PCR reaction had a total volume 25 μl containing 16.24 μl of H2O, 2 μl 
of 10x PCR buffer, 2.0 μl of 2.5 mM dNTP, 2.0 μl of 25 mM MgCL2, 0.5 μl of 10 mg/ml BSA, 
1.3 μl 50 μM ITS1-Fx and ITS1-Rx primers, 0.2 μl 50 μM ITS1 probe and 0.3 μl of 5 U/ μl 
FastStart Taq DNA polymerase (Roche Applied Science, Indianapolis, IN). One microliter of 
purified DNA was added as template and PCR reaction mix was transferred to 25 μl Cepheid 
PCR tubes. The reaction was carried out using a Smart Cycler (v2.0b, Cepheid, Sunnyvale, CA) 
with the following conditions: 94ºC for 60 sec, then 50 cycles of 92ºC for 15 sec, 52ºC for 30 sec 
and 72ºC for 40 sec. The Ct for each sample was compared to the standard controls (10
7
 to 10
3 
parasites/ml and negative) to estimate the concentration of parasite per gram of spleen. 
FACS analysis. Virulent Type I (GT1), Intermediate Type II (PTG) and NON virulent Type III 
(CTG) strains were used for this assay. Uninfected mice served as negative control. Parasites 
were grown and maintained in T25 vented culture flasks at 37°C with 5% CO2 as described 
above. 6 -8 week old CD-1 outbred female mice were I.P. injected with 500 tachyzoites of each 
strain. On day 5, peritoneal lavage was collected, purified and counted as described above. 1 x 
10
6
 cells were transferred to a 96-well plate and washed. Cells were blocked for 1 hour with 
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FACS buffer (PBS + 1% BSA). Cell populations were characterized by flow cytometry using PE 
conjugated Ly-6G Ab (eBioscience # 12-5931-82), FITC conjugated F4/80 (eBioscience # 11-
4801-82) and APC conjugated CD11c (eBioscience #17-0114-82). Samples were acquired on a 
FACSCalibur (BD Biosciences) cytometer collecting 50,000 events. 
Results  
Type I and II modulate more host genes than Type III during infection overall.  
 For microarray analysis, RNA collected from peritoneal lavage of three mice infected 
with GT1, PTG and CTG were used for gene expression profiling during T. gondii infection. 
Differentially expressed genes were clustered and identified based on signal intensity values and 
fold change differences between strains compared to untreated mice. In brief, those genes with at  
least a two-fold change in expression values was considered. Differentially expressed genes 
among treatments were categorized based on biological processes via OntoExpress 
(vortex.cs.wayne.edu/ontoexpress). Our results showed that inoculation with Type I and II 
parasites affected more genes in mice compared to that of the Type III strain (TABLE 3-2). In 
particular, infection with Type I T. gondii caused the induction of 1,180 genes and the repression 
of 1,740genes. Type II infection induced 950 genes and repressed 1,335 genes. In contrast to this 
trend more genes (781 genes) were induced while less (709 genes) were repressed overall with 
Type III infection. 
Analysis of microarray data  
As described above, analysis of variance (ANOVA) statistical method was used to select 
significantly expressed genes in either up- or down-regulated based on signal intensity values. 
Using the average signal intensity value from three mice for GT1 and CTG, and two mice for 
PTG, cluster analysis visually revealed two levels of comparison: 1) gene expression comparison  
 35 
Table 3-2. Number of host genes affected by T. gondii at day 5 post infection.  
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Figure 3-1. Hierarchical clustering analysis. HCA for classification of differential gene 
expression patterns in CD-1 outbred mice at day 5 post infection with T. gondii GT1, PTG and 
CTG strains. Gene expression signal intensity values were compared to negative control mice 
(NEG) that are not infected with T. gondii. Red indicates up-regulated signals; blue indicates 
down-regulated signals 
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of negative control mice compared to Type I, II and III infected mice and 2) gene expression 
comparison between T. gondii strain infections. Results showed that in mice infected with the 
three types of T. gondii, the overall gene expression patterns were similar when compared to the 
negative controls (Figure. 3-1). When comparing gene expression among mice infected with the 
three T. gondii lineages, Type III (CTG) infected mice had a distinct expression pattern from that 
of the Type I and II lineages (Figure. 3-1.)  
Differentially expressed genes among treatments compared to untreated mice infections 
were further analyzed using OntoExpress (vortex.cs.wayne.edu/ontoexpress) to identify 
alterations to gene expression profiles for specific functional groups. We analyzed gene 
expression profiles for several biological processes including immune response, inflammatory 
response, oxidation reduction, signal transduction, transcription, translation, transport, apoptosis 
and cell cycle for both induced and repressed genes (Figure. 3-2. A-I and TABLE 3-5). Fold 
change values of differentially expressed genes were natural log transformed to generate graphs 
for each functional group.  
The immune response category had the highest number of genes induced among all 
groups. Type I strain GT1 infection induced 82 genes and repressed 26 genes while PTG induced 
73 genes and repressed 16 genes. Type III strain CTG induced 76 genes and repressed only 10 
genes (TABLE 3-1). In this category, cytokines including CCL22, CCL12, CCL8, CCL7, CCL3 
and IFN-γ were highly expressed compared to uninfected mice (TABLE 3-5). These genes were 
induced at higher levels in mice infected with Type I strain, compared to infections with Type II 
and III strains. Gene expression in mice infected with Type II strain remained intermediate 
between Type I and III infections, but more similar to Type I (FIG.3-2.A).
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CTG: 1.2 ± 1.0 
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Figure. 3-2. A-I. Comparison of gene expression profiles for Type I, II and III infection 
based on biological processes. Shown are genes that were significantly up- or down-regulated 
during infection. Genes were categorized based on biological function. 
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 Inflammatory response was a specific immune response significantly altered as a result of 
infection. Virulent strain GT1 and intermediately virulent strain PTG overall expression patterns 
were very similar. CTG again elicited a milder response compared to virulent and intermediate 
infections for genes both induced and repressed. Specifically, Type I strain GT1 infection 
induced 38 genes and repressed 8 genes while PTG induced 30 genes and repressed 7 genes. 
Type III CTG induced 4 genes and repressed only 10 genes. The same 3 genes, Tryptase beta-2 
(Tpsb2), Thrombospondin 1 (Thbs1) and C-X-C motif chemokine 13 (Cxcl13) were 
dowregulated by 2 fold among all three infections. The number of differentially expressed genes 
down-regulated is significantly lower than those up-regulated (TABLE 3-1). Among differential  
expressed genes induced, Type I and II infections share similar expression profiles. Type III 
expression does not follow a clear trend (Figure. 3-2.B). 
Oxidation reduction was another process determined to be altered during T. gondii 
infection. A total of 35, 31 and 31 genes belonging to this group were induced during Type I, II 
and III infection, respectively. Many genes overlapped between infections. The number of genes  
repressed during Type I (63 genes) and Type II (46 genes) infections surpassed the number of 
genes induced.  Type III CTG only repressed 14 genes (TABLE 3-1). Repressed genes involved 
in oxidation reduction biological process followed a similar expression profile among Type I and 
II infection. Gene profiling of Type III repressed genes show the similar suppression trend of 
Type I and II but to a lesser extent (Figure.3-2. C).  
In the remaining categories (signal transduction, transcription, translation, transport, 
apoptosis and cell cycle), we observed a similar phenomenon described above (Figure. 3-2. D-I). 
Type I and II had similar expression patterns compared to Type III. Collectively, an overall trend 
of polarized expression among the type I, II and III strains was detected. This polarization 
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characteristic was highly observed among repressed genes. Our results showed that expression is 
driven in two different directions, dependent on parasite genetic background. 
Microarray validation via RT-PCR 
 In order to validate our microarray data, 5 most highly up-regulated and 6 most down-
regulated genes were selected. The 5 most up regulated genes selected were CCL22, CCL17, 
CCL12, CCL7 and CCL2, and the 6 highly repressed genes selected were Prg4, Serpinb2, 
Serpinb10, ApoE, Fabp7 and Marco (TABLE 3-3). The RT-PCR expression data of these 11 
genes showed similar trends during Type I and II infections. Although, the highly repressed 
genes share similar trends during Type III infection, the highly upregulated genes were 
downregulated based on RT-PCR data (Table. 3-4). 
Determine parasite load in the spleen tissues of mice by RT-PCR  
Parasite load in the spleen of mice infected with 500 tachyzoites of GT1, CTG and PTG 
was quantified. On day 5 post IP, the Log (parasites/g spleen) was 6.7 (s.d. = 1.0) for virulent 
strain GT1. This was more than 300 times higher than intermediate PTG which was 3.6 (s.d= 
0.8) and non virulent CTG which was 2.4 (s.d. = 0.2) (FIG. 3-3). 
Characterization of host cell population 
 FACS analysis revealed that Type I GT1 (Figure 3-4) infection dendritic cells comprised 
~ 46 % of live cells gated, while macrophages were only 5% and neutrophils were ~ 45 %. Type 
II PTG (Figure 3-4)  peritoneal lavage cells followed a very similar trend to Type I infection 
being composed of composed of ~ 50% , ~8% and 22% of dendritic cell, macrophages and 
neutrophils, respectively. Lastly, during Type III CTG, dendritic cells were composed of 57% of 
cell population, followed by neutrophils with 29% and macrophages being ~ 3% (Figure 3-4.A-
I). 
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Gene 
RT-PCR (2
-ΔΔCT
) 
     GT1           PTG            CTG 
Prg4 -9.8 -8.6 -3.0 
Serpinb2 -9.2 -7.3 -2.9 
Serpinb10 -8.7 -10.1 -1.9 
ApoE -7.6 -9.5 -3.1 
Fabp7 -9.7 -5.1 -1.9 
Marco -8.6 -7.2 0.2 
    
CCL2 3.7 4.1 -0.9 
CCL7 3.8 4.9 0.4 
CCL12 4.1 5.0 -3.4 
CCL17 1.9 -5.1 -5.8 
CCL22 2.6 1.4 -3.9 
    
 
 
Table 3-3. Most highly up or down regulated genes 
 
Table 3-4. Microarray validation 
 
 
 
 
 
 
 
 
 
Table 3-4. Validation of microarray using reverse transcriptase PCR (RT) data. The table 
shows 2^-ΔΔCt values obtained from RT-PCR for 11 genes up or down regulated during GT1, 
PTG and CTG infection. Gapdh was used as an internal control for expression comparison.  
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Figure 3-3. Parasite burdens (Log parasites/g spleen) in mice at day 5 post IP. Parasite load 
was determined via RT-PCR. GT1 has a significantly high parasite burden than that of PTG and 
CTG (*P = 0.001, ANOVA). 
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Figure. 3-4.A-L. Host cell population from peritoneal lavage during in vivo infection. Flow 
cytometric contour plots show expression of CD11c , F4/80 and Ly-6G in Type I (A-C), Type II 
(E-F), Type III (G-I) compared to uninfected (J-L). Data from a representative experiment 
performed in duplicate are shown.  
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Figure 3-5 A-C. Bar diagrams of FACS analysis after T. gondii infection in vivo. Bar 
diagrams show the percent host cell expression of individual mice samples. Each bar represents 
one individual mouse sample. Cells were stained with CD11c (A), F4/80 (B) or Ly-6 (C) for 
each treatment.   
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Functional 
Class 
Accession 
no. 
Gene Name (Gene symbol) Fold Change in Transcription 
vs. NEG mice 
GT1            PTG          CTG 
Immune 
Response 
NM_021274 Chemokine (C-X-C motif) ligand (Cxcl10) 191.8 156 62.6 
 NM_15351 Interleukin 1 family, member 9 (Il1f9) 67 32.2 13.9 
 NM_011579 T-cell specific GTPase (Tgtp) 65.6 63.5 63.4 
 NM_011331 Chemokine (C-C motif) ligand 12 (CCL12) 57.9 26.4 11.9 
 NM_008361 Interleukin 1 beta (Il1b) 57.2 37.5 12.9 
 NM_008599 Chemokine (C-X-C motif) ligand 9 (Cxcl9) 40 52.4 28.1 
 NM_011337 Chemokine (C-C motif) ligand 3 (CCL3) 35.6 19.4 12.2 
 NM_001038
604 
C-type lectin domain family 5, member a (Clec5a) 31 16.7 9.1 
 NM_138648 Oxidized low density lipoprotein (lectin-like) 
receptor 1 (Olr1) 
29.7 2.2 2.2 
 NM_020001 C-type lectin domain family 4, member n (Clec4n) 28.2 13.6 10.7 
 NM_153564 Guanylate binding protein 5 (Gbp5) 28.1 26.9 24.3 
 NM_010260 Guanylate binding protein 2 (Gbp2) 27 26 21.6 
 NM_011854 2'-5' oligoadenylate synthetase-like 2 (Oasl2) 27 22.5 15.8 
 NM_013654 Chemokine (C-C motif) ligand 7 (CCl7) 26 12.3 4.2 
 NM_021443 Chemokine (C-C motif) ligand 8 (CCl8) 23.8 23.8 10 
 NM_008326 Immunity-related GTPase family M member 
(1Irgm1) 
20.1 18.6 20.7 
 NM_010259 Guanylate binding protein 1 (Gpb1) 19.9 30.9 55 
 NM_008337 Interferon gamma (Ifng) 17.8 18 9.5 
 NM_031167 Interleukin 1 receptor antagonist (Il1rn) 16.8 8.9 4.1 
 NM_009778 Complement component 3 (C3) 14.2 16.8 15.1 
 NM_009137 chemokine (C-C motif) ligand 22 (CCL22) 12.9 2.8 2.4 
 NM_013683 Transporter 1, ATP-binding cassette, sub-family B 
(Tap1) 
9.6 10.3 9 
 NM_030150 DEXH (Asp-Glu-X-His) box polypeptide 58 
(Dhx58) 
8.2 7.8 7.3 
 NM_019494 Chemokine (C-X-C motif) ligand 11(Cxcl11) 7.4 6.9 2.2 
 NM_145634 CD300 antigen like family member F (CD300lf) 7.1 4.4 3.4 
 NM_018866 Chemokine (C-X-C motif) ligand 13 (Cxcl13) -81.4 -65.6 -23.4 
 NM_019932 Platelet factor 4 (Pf4) -55.2 -73.7 -31.7 
 NM_007572 Complement component 1, q subcomponent, alpha 
polypeptide (C1qa) 
-7.9 -3.7 NS 
 NM_009888 Complement component factor h (Cfh) -6.4 -6.6 NS 
 NM_130449 Collectin sub-family member 12 (Colec12) -6.2 -6.4 -4.0 
 NM_007574 Complement component 1, q subcomponent, C 
chain (C1qc) 
-5.8 NS 2.7 
 NM_010016 CD55 antigen (Cd55) -5.3 -3.4 NS 
 NM_009777 complement component 1, q subcomponent, beta 
polypeptide (C1qb) 
-4.2 -2.0 NS 
 NM_007758 Complement receptor 2 (Cr2) -4.2 -3.2 NS 
 
 
 
 
NM_009884 CCAAT/enhancer binding protein (C/EBP), 
gamma (Cebpg) 
-3.1 -3.0 -2.5 
    
Table 3-5. Gene expression ratio of category specific genes modulated during T. gondii infection     
compared to NEG 
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Functional 
Class 
Accession 
no. 
Gene Name (Gene symbol) Fold Change in Transcription 
vs. NEG mice 
   GT1            PTG          CTG 
 NM_033622 Tumor necrosis factor (ligand) superfamily, 
member 13b (Tnfsf13b) 
-2.4  
-2.5 
 
-3.1 
 NM_001037
719 
B and T lymphocyte associated (Btla) -2.4 NS NS 
 NM_013499 Complement component (3b/4b) receptor 1-like 
(Cr1l) 
-2.2 NS NS 
 NM_133829 Major facilitator superfamily domain containing 6 
(Mfsd6) 
-2.2 NS NS 
 NM_008339 CD79B antigen (Cd79b) -2.2 NS NS 
 NM_001012
477 
Chemokine (C-X-C motif) ligand 12 (Cxcl12) -2.2 -2.1 -2.3 
 NM_027987 CD300 antigen like family member G (Cd300lg) -2.2 -2.0 NS 
 NM_009403 Tumor necrosis factor (ligand) superfamily, 
member 8 (Tnfsf8) 
-2.1 NS NS 
 NM_199221 CD300 antigen like family member B (Cd300lb) -2.1 -2.4 NS 
 ENSMUST0
0000060105 
Retinoic acid early transcript 1E (Raet1e) -2.1 -2.0 -2.1 
 NM_010389 Histocompatibility 2, O region beta locus (H2-ob) -2.0 NS NS 
 NM_008176 Chemokine (C-X-C motif) ligand 1 (Cxcl1) -2.0 -2.3 -2.0 
      
Inflammatory 
Response 
NM_021274 Chemokine (C-X-C motif) ligand (Cxcl10) 191.8 156.0 62.6 
 NM_009892 Chitinase 3-like 3 (Chi3l3) 96.4 68.3 38.3 
 NM_011331 Chemokine (C-C motif) ligand 12 (CCL12) 57.9 26.4 11.9 
 NM_008361 Interleukin 1 beta (Il1b) 57.2 37.5 12.9 
 NM_008599 Chemokine (C-X-C motif) ligand 9 (CxCl9) 39.9 52.4 28.1 
 NM_011337 Chemokine (C-C motif) ligand 3 (CCL3) 35.6 19.4 12.2 
 NM_138648 Oxidized low density lipoprotein (lectin-like) 
receptor 1 (Olr1) 
29.7 2.2 2.2 
 NM_011333 Chemokine (C-C motif) ligand 2 (Ccl2) 29.4 11.8 4.3 
 NM_013654 Chemokine (C-C motif) ligand 7  (CCL7) 26.0 12.3 4.2 
 NM_021443 Chemokine (C-C motif) ligand 8 (CCL8) 23.8 23.8 10.0 
 NM_009778 complement component 3  (C3) 14.2 16.8 15.1 
 NM_010927 nitric oxide synthase 2, inducible (Nos2) 13.4 12.1 3.5 
 NM_009137 Chemokine (C-C motif) ligand 22 (CCL22) 12.9 2.8 2.4 
 NM_019494 Chemokine (C-X-C motif) ligand 11 (Cxcl11) 7.4 6.9 2.2 
 NM_013652 Chemokine (C-C motif) ligand 4  (CCL4) 6.5 2.6 2.3 
 NM_009915 Chemokine (C-C motif) receptor 2 (CCr2) 6.0 7.4 9.5 
 NM_013693 Tumor necrosis factor  (Tnf) 5.4 4.6 3.0 
 NM_020008 C-type lectin domain family 7, member a  (Clec7a) 4.6 2.1 2.3 
 NM_013653 Chemokine (C-C motif) ligand 5 (CCl5) 3.9 4.6 7.5 
 NM_010851 Myeloid differentiation primary response gene 88 
(Myd88) 
3.8 3.6 2.4 
 NM_011610 Tumor necrosis factor receptor superfamily, 
member 1b (Tnfrsf1b) 
3.8 4.3 3.7 
 NM_010554 Interleukin 1 alpha (Il1a) 3.4 NS 2.5 
 NM_145126 Chitinase 3-like 4 (Chi3l4) 3.2 2.9 2.4 
 NM_009140 Chemokine (C-X-C motif) ligand 2C (Cxcl2) 3.1 NS NS 
Table 3-5. Continued 
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Functional 
Class 
Accession 
no. 
Gene Name (Gene symbol) Fold Change in Transcription 
vs. NEG mice 
   GT1            PTG          CTG 
 NM_145636 Interleukin 27 (Il27) 3.1 3.0 3.1 
 NM_018866 Chemokine (C-X-C motif) ligand 13(Cxcl13) -81.4 -65.6 -23.4 
 NM_011347 Selectin, platelet (Selp) -17.7 -13.0 NS 
 NM_010781 Tryptase  beta 2 (Tpsb2) -4.2 -3.1 -2.4 
 NM_021439 Carbohydrate sulfotransferase 11 (Chst1) 2.3 NS NS 
 NM_011580 Thrombospondin 1(Thbs1) -8.4 -13.4 -4.5 
 NM_007553 Bone morphogenetic protein 2 (Bmp2) -2.7 -3.8 NS 
      
Oxidation 
Reduction 
NM_009890 Cholesterol 25-hydroxylase  (Ch25h) 39.4 23.1 14.8 
 NM_010927 Nitric oxide synthase 2, inducible (Nos2) 13.4 12.1 3.5 
 NM_011198 Prostaglandin-endoperoxide synthase 2 (Ptgs2) 12.7 3.3 2.0 
 NM_019698 Aldehyde dehydrogenase 18 family, member A1 
(Aldh18a1) 
7.7 8.6 7.3 
 NM_054098 STEAP family member 4 (Steap4) 7.6 5.1 2.5 
 NM_009104 Ribonucleotide reductase M2 (Rrm2) 7.0 8.2 7.1 
 NM_013671 Superoxide dismutase 2, mitochondrial (Sod2) 7.0 6.9 4.1 
 NM_145533 Spermine oxidase  (Smox) 6.9 3.9 2.6 
 NM_175521 
Dehydrogenase/reductase (SDR family) member 9 
(Dhrs9) 
5.7 3.4 3.7 
 NM_010442 Heme oxygenase (decycling) 1 (Hmox1) 3.8 3.3 2.9 
 NM_001012
306 
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- 
and ste (Hsd3b3) 
3.3 3.4 3.1 
 NM_010344 Glutathione reductase  (Gsr) 3.3 3.7 3.2 
 NM_008638 Methylenetetrahydrofolate dehydrogenase (NAD+ 
dependent) (Mthfd2) 
3.3 2.6 2.1 
 NM_008898 Perforin 1 (pore forming protein)  (Por) 3.2 2.2 NS 
 NM_010274 Glycerol phosphate dehydrogenase 2, 
mitochondrial  (Gpd2) 
3.1 3.5 2.8 
 ENSMUST0
0000082392 
NADH dehydrogenase subunit 1 (ND1) 3.2 2.5 NS 
 NM_013759 Selenoprotein X 1 (Sepx1) 3.0 2.8 3.0 
 NM_008084 Glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) 
2.9 2.7 2.8 
 NM_001081
274 
Phosphogluconate dehydrogenase  (Pgd) 2.7 2.3 3.0 
 NM_008324 Indoleamine 2,3-dioxygenase 1 (Ido1) 2.6 3.4 2.6 
 NM_019468 Glucose-6-phosphate dehydrogenase 2 (G6pd2) 2.6 2.7 3.1 
 NM_009103 Ribonucleotide reductase M1 (Rrm1) 2.6 2.8 2.7 
 NM_008062 Glucose-6-phosphate dehydrogenase X-linked 
(G6pdx) 
2.5 2.9 3.3 
 ENSMUST0
0000054963 
Farnesyl diphosphate farnesyl transferase 1 (Fdft1) 2.5 3.3 4.1 
 NM_008617 Malate dehydrogenase 2, NAD (mitochondrial) 
(Mdh2) 
2.5 2.0 2.1 
 NM_009660 Arachidonate 15-lipoxygenase  (Alox15) -21.2 -51.2 -4.2 
 NM_178767 Transmembrane protein 195 (Tmem195) -17.0 -12.1 NS 
 NM_008969 Prostaglandin-endoperoxide synthase 1 (Ptgs1) -6.8 -5.6 NS 
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 NM_178600 Vitamin K epoxide reductase complex, subunit 1 
(Vkorc1) 
-6.3 -4.8 -2.9 
 NM_183158 Cytochrome P450, family 2, subfamily ab, 
polypeptide 1 (Cyp2ab1) 
-6.0 -5.3 NS 
 NM_010497 Isocitrate dehydrogenase 1 (NADP+), soluble 
(Idh1) 
-5.9 -3.6 NS 
 NM_011830 Inosine 5'-phosphate dehydrogenase 2 (Impdh2) -5.2 -4.2 -2.4 
 NM_030004 Crystallin, lambda 1 (Cryl1) -4.9 -4.9 -2.1 
 NM_019779 Cytochrome P450, family 11, subfamily a, 
polypeptide 1  (Cyp11a1) 
-4.8 -4.2 -3.3 
 NM_025522 Dehydrogenase/reductase (SDR family) member 7 
(Dhrs7) 
-4.7 -3.9 NS 
 NM_001136
084 
Tryptophan hydroxylase 1 (Tph1) -4.3 -4.1 -2.4 
 NM_009662 Arachidonate 5-lipoxygenase  (Alox5) -4.1 -5.2 NS 
 NM_013778 Aldo-keto reductase family 1, member C13 
(Akr1c13) 
-3.7 -4.4 -2.3 
 NM_172778 Monoamine oxidase B  (Maob) -3.5 -3.5 -2.7 
 NM_010008 Cytochrome P450, family 2, subfamily j, 
polypeptide 6 (Cyp2j6) 
-3.4 -3.7 NS 
 NM_026172 2,4-dienoyl CoA reductase 1, mitochondrial  
(Decr1) 
-3.1 -2.0 NS 
 NM_016764 Peroxiredoxin 4 (Prdx4) -3.0 -2.8 -2.2 
 NM_008160 Glutathione peroxidase 1 (Gpx1) -3.0 NS NS 
 NM_020282 NAD(P)H dehydrogenase, quinone 2 (Nqo2) -3.0 -2.4 NS 
 NM_008278 Hydroxyprostaglandin dehydrogenase 15 (NAD)  
(Hpgd) 
-3.0 -3.1 NS 
 NM_027534 3-ketodihydrosphingosine reductase (Kdsr) -2.9 -2.4 NS 
 ENSMUST0
0000023559 
Enoyl-Coenzyme A, hydratase/3-hydroxyacyl 
Coenzy  (Ehhadh) 
-2.8 -2.5 -2.2 
 NM_008212 Hydroxyacyl-Coenzyme A dehydrogenase  (Hadh) -2.7 -2.1 NS 
 NM_146090 Zinc binding alcohol dehydrogenase, domain 
containing 2 (Zadh2) 
-2.7 -2.4 NS 
 NM_030017 Retinol dehydro;genase 12 (Rdh12) -2.7 -2.3 NS 
      
Signal 
Transduction 
NM_009909 Interleukin 8 receptor, beta  (Il8rb) 26.1 15.3 6.5 
 NM_010259 Linker for activation of T cells (Lat) 19.9 30.9 55.1 
 NM_181754 G protein-coupled receptor 141 (Gpr141) 15.3 24.2 20.1 
 NM_028808 Purinergic receptor P2Y, G-protein coupled 13 
(P2ry13) 
9.2 9.2 4.1 
 NM_009283 Signal transducer and activator of transcription 1 
(Stat1) 
9.2 9.3 8.3 
 NM_010553 Interleukin 18 receptor accessory protein (Il18rap) 7.5 9.2 7.7 
 NM_016846 Ral guanine nucleotide dissociation stimulator,-like 
1 (Rgl1) 
7.1 7.4 4.9 
 NM_030720 G protein-coupled receptor 84 (Gpr84) 6.9 4.1 3.7 
 NM_009915 Chemokine (C-C motif) receptor 2 (Ccr2) 6.0 7.4 9.5 
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 NM_028595 Membrane-spanning 4-domains, subfamily A, 
member 6C (Ms4a6c) 
5.8 5.5 5.6 
 NM_026835 Membrane-spanning 4-domains, subfamily A, 
member 6D (Ms4a6d) 
5.8 4.7 4.6 
 NM_008365 Interleukin 18 receptor 1 (Il18r1) 4.9 8.4 8.2 
 NM_017466 CCr12 4.9 3.0 2.7 
 NM_008152 G-protein coupled receptor 65 (Gpr65) 4.8 4.4 3.6 
 NM_020260 CDC42 GTPase-activating protein  (Cdgap) 4.7 3.4 3.0 
 NM_019963 Signal transducer and activator of transcription 2 
(Stat2) 
4.5 4.7 3.1 
 NM_011332 Chemokine (C-C motif) ligand 17 (CCL17) 3.9 2.0 NS 
 NM_010851 Myeloid differentiation primary response gene 88 
(Myd88) 
3.8 3.6 2.4 
 NM_010431 Hypoxia inducible factor 1, alpha subunit (Hif1a) 3.8 2.9 2.1 
 NM_030701 G protein-coupled receptor 109A  (Gpr109a) 3.7 2.0 2.5 
 NM_153067 MAS-related GPR, member A3 (Mrgpra3) 3.5 2.3 NS 
 NM_008042 Formyl peptide receptor 3 (Fpr3) 3.4 3.4 2.9 
 NM_008315 5-hydroxytryptamine (serotonin) receptor 7 (Htr7) 3.4 2.7 NS 
 NM_009539 Zeta-chain (TCR) associated protein kinase 
(Zap70) 
3.4 4.7 4.3 
 NM_025278 Guanine nucleotide binding protein (G protein), 
gamma 12 (Gng12) 
3.3 2.7 2.2 
 NM_001099
624 
Rap guanine nucleotide exchange factor (GEF) 2 
(Rapgef2) 
3.1 2.9 2.3 
 NM_009910 Chemokine (C-X-C motif) receptor 3 (Cxcr3) 3.1 4.2 6.0 
 NM_145630 Pyruvate dehydrogenase kinase, isoenzyme 3 
(Pdk3) 
3.0 2.8 3.0 
 NM_009917 Chemokine (C-C motif) receptor 5 (Ccr5) 3.0 3.5 3.6 
 BC119501 G protein-coupled receptor 15 (Gpr15) 3.0 3.0 2.7 
 NM_010177 Fas ligand 1 (Fasl) 3.0 3.9 4.4 
 NM_010177 Fas ligand (Fas) 3.0 3.9 4.4 
 ENSMUST0
0000058535 
G protein-coupled receptor 149 (Gpr149) 2.8 2.1 2.5 
 NM_146934 Olfactory receptor 46 (Olfr46) 2.7 2.9 NS 
 NM_053240 Vomeronasal 1 receptor, B10 (V1rb10) 2.7 2.4 NS 
 NM_053227 Vomeronasal 1 receptor, B4 (V1rb4) 2.7 2.0 NS 
 NM_146718 Olfactory receptor 430 (Olfr430) 2.6 3.4 2.6 
 NM_013875 Phosphodiesterase 7B (Pde7b) 2.6 3.0 2.7 
 NM_008364 Interleukin 1 receptor accessory protein  (Il1rap) 2.6 NS NS 
 NM_030682 Toll-like receptor 1 (Tlr1) 2.5 2.3 2.1 
 NM_008561 Melanocortin 3 receptor (Mc3r) 2.4 NS NS 
 ENSMUST0
0000020547 
Vomeronasal 2, receptor 81 (Vmn2r81) 2.4 2.2 NS 
 NM_007429 Angiotensin II receptor, type 2 (Agtr2) 2.4 NS NS 
 NM_183168 Pyrimidinergic receptor P2Y, G-protein coupled, 6 
(P2ry6) 
2.3 2.6 4.5 
 NM_205820 Toll-like receptor 13 (Tlr13) 2.3 2.0 3.0 
 NM_133193 Interleukin 1 receptor-like 2 (Il1rl2) 2.3 2.1 2.2 
 NM_029522 G-protein signalling modulator 2 (Gpsm2) 2.3 2.5 2.9 
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 NM_198961 Vomeronasal 2, receptor 43 (Vmn2r43) 2.2 2.6 NS 
 NM_146265 Olfactory receptor 1506 (Olfr1506) 2.2 2.6 NS 
 NM_019925 G protein-coupled receptor 132 (Gpr132) 2.2 2.3 NS 
 NM_007577 Complement component 5a receptor 1 (C5ar1) 2.2 2.0 2.0 
 NM_029523 DEP domain containing 1a (Depdc1a) 2.2 2.7 2.6 
 NM_146383 Olfactory receptor 460 (Olfr460) 2.2 NS NS 
 NM_009421 Tnf receptor-associated factor 1 (Traf1) 2.2 2.1 NS 
 NM_021297 Toll-like receptor 4  (Tlr4) 2.2 NS 2.1 
 NM_001081
211 
Platelet-activating factor receptor  (Ptafr) 2.2 2.4 2.2 
 NM_019408 Nuclear factor of kappa light polypeptide (Nfkb2) 2.1 NS NS 
 NM_008519 Leukotriene B4 receptor 1 (Ltb4r1) 2.1 NS 3.3 
 NM_001011
863 
Olfactory receptor 406 (Olfr406) 2.1 2.4 NS 
 NM_146879 Olfactory receptor 330 (Olfr330) 2.1 2.4 NS 
 NM_025658 Membrane-spanning 4-domains, subfamily A, 
member 4D (Ms4a4d) 
2.1 2.0 NS 
 NM_010341 Neuromedin U receptor 1 (Nmur1) 2.1 NS NS 
 NM_198895 Active BCR-related gene (Abr) 2.1 2.0 NS 
 NM_010185 Fc receptor, IgE, high affinity I, gamma 
polypeptide (Fcer1g) 
2.1 2.0 2.2 
 NM_178589 Tumor necrosis factor receptor superfamily, 
member 21(Tnfrsf21) 
2.1 NS 2.4 
 NM_207573 Olfactory receptor 1380 (Olfr1380) 2.1 2.0 NS 
 NM_029094 Phosphatidylinositol 3-kinase, catalytic, beta 
polypeptide (Pik3cb) 
2.1 NS NS 
 NM_213659 Signal transducer and activator of transcription 3 
(Stat3) 
2.0 2.1 2.0 
 NM_147104 Olfactory receptor 550 (Olfr550) 2.0 2.3 NS 
 NM_207253 Olfactory receptor 1371(Olfr1371) 2.0 NS NS 
 NM_028724 Ras and Rab interactor 2 (Rin2) 2.0 NS NS 
 NM_010437 Human immunodeficiency virus type I enhancer 
binding protein 2 (Hivep2) 
2.0 NS NS 
 NM_008159 G protein-coupled receptor 33  (Gpr33) 2.0 2.0 2.6 
 NM_001011
867 
Olfactory receptor 538 (Olfr538) 2.0 2.1 NS 
 NM_010170 Coagulation factor II (thrombin) receptor-like 2 
(F2rl2) 
2.0 NS 2.1 
 NM_146593 Olfactory receptor 1111 (Olfr1111) -24.3 -23.2 -9.5 
 NM_011158 Protein kinase, cAMP dependent regulatory 
(Prkar2b) 
-17.0 -13.1 -2.1 
 NM_023653 Wingless-related MMTV integration site 2 (Wnt2) -14.5 -11.1 -2.3 
 NM_008839 Phosphatidylinositol 3-kinase, catalytic, alpha 
polypeptide (Pik3ca) 
-12.2 -12.7 -2.7 
 NM_130862 Brain-specific angiogenesis inhibitor 1-associated 
protein (Baiap2) 
-10.4 -6.1 -2.0 
 NM_007489 Aryl hydrocarbon receptor nuclear translocator-like 
(Arntl) 
-9.2 -8.0 -6.0 
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 NM_001011
530 
Olfactory receptor 723 (Olfr723) -9.1 -8.4 -7.3 
 NM_146606 Olfactory receptor 24 (Olfr24) -7.8 -3.8 NS 
 NM_053190 Sphingosine-1-phosphate receptor 5 (S1pr5) -7.4 -6.7 -5.1 
 NM_007551 chemochine (C-X-C motif) receptor 5 (Cxcr5) -7.1 -4.9 -2.7 
 NM_001039
692 
Rho GTPase activating protein 12 (Arhgap12) -6.5 -5.7 -4.6 
 NM_023121 Guanine nucleotide binding protein (G protein) 
(Gngt2) 
-6.0 -5.3 -3.5 
 NM_139138 EGF-like module containing, mucin-like, hormone 
receptor-like 4 (Emr4) 
-5.7 -5.4 -5.1 
 NM_022420 G protein-coupled receptor, family C, group 5, 
member B  (Gprc5b) 
-5.6 -3.8 -2.5 
 BC087872 Guanine nucleotide binding protein (G protein), 
gamma 5 (Gng5) 
-4.8 -4.9 NS 
 NM_009707 Rho GTPase activating protein 6 (Arhgap6) -4.6 -4.4 -3.1 
 NM_009706 Rho GTPase activating protein 5 (Arhgap5) -3.9 -2.7 NS 
 NM_007995 Ficolin A  (Fcna) -3.9 -3.8 NS 
  
NM_001081
298 
 
Latrophilin 2 (Lphn2) 
- 
-3.8 
 
-3.8 
 
NS 
 NM_172671 Leucine-rich repeat-containing G protein-coupled 
receptor 4 (Lgr4) 
-3.7 -3.9 -3.2 
 NM_001033
251 
G protein-coupled receptor 174 (Gpr174) -3.7 -2.8 NS 
 NM_013516 Membrane-spanning 4-domains, subfamily A, 
member 2 (Ms4a2) 
-3.6 -2.9 NS 
 NM_010184 Fc receptor, IgE, high affinity I, alpha polypeptide 
(Fcer1a) 
-3.6 -3.3 -2.5 
 NM_001122
998 
Tiam2 (Tiam2) -3.0 -2.4 NS 
 NM_001122
759 
Phosphodiesterase 7A  (Pde7a) -2.9 -2.8 NS 
 NM_001008
548 
Phosphodiesterase 2A, cGMP-stimulated  (Pde2a) -2.8 
 
-2.6 NS 
 NM_018869 G protein-coupled receptor kinase 5 (Grk5) -2.7 -2.1 NS 
 AK129042 Protein phosphatase 2, regulatory subunit B 
(Ppp2r5c) 
-2.6 NS -3.2 
 NM_008137 Guanine nucleotide binding protein, alpha 14 
(Gna14) 
-2.5 -2.4 NS 
 NM_133222 EGF, latrophilin seven transmembrane domain 
containing 1 (Eltd1) 
-2.5 -2.6 NS 
 NM_001011
852 
Olfactory receptor 1029 (Olfr1029) -2.5 -3.1 -2.3 
 NM_007641 Membrane-spanning 4-domains, subfamily A, 
member 1 (Ms4a1) 
-2.5 -2.6 NS 
 NM_007904 Endothelin receptor type B (Ednrb) -2.4 -2.4 NS 
 NM_010332 Endothelin receptor type A (Ednra) -2.4 -2.0 NS 
 NM_146903 Olfactory receptor 871 (Olfr871) -2.4 -2.2 -2.0 
 NM_019917 Vomeronasal 2, receptor 26 (Vmn2r26) -2.4 -2.4 NS 
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 NM_144800 Metastasis suppressor 1 (Mtss1) -2.3 NS NS 
 NM_007901 Sphingosine-1-phosphate receptor 1 (S1pr1) -2.3 -3.1 -2.4 
 NM_022985 Zinc finger, AN1-type domain 6 (Zfand6) -2.3 NS NS 
 NM_153820 Rho GTPase activating protein 15 (Arhgap15) -2.3 -2.1 -2.0 
 NM_011739 Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase (Ywhaq) 
-2.2 -2.2 NS 
 NM_175531 MAS-related GPR, member B2 (Mrgprb2) -2.2 -2.0 NS 
 BC031465 Family with sequence similarity 13, member B 
(Fam13b) 
-2.2 -2.7 -3.0 
 NM_001034
868 
MAS-related GPR, member X2 (Mrgprx2) -2.1 NS NS 
 NM_138956 Ras association (RalGDS/AF-6) domain family 
member 3 (Rassf3) 
-2.1 NS -2.0 
 NM_183031 G protein-coupled receptor 183 (Gpr183) -2.1 -2.2 -2.3 
 NM_147070 Olfactory receptor 604  (Olfr604) -2.1 NS NS 
 NM_133926 calcium/calmodulin-dependent protein kinase I 
(Camk1) 
-2.1 NS NS 
 NM_172525 Rho GTPase activating protein 29 (Arhgap29) -2.0 NS NS 
 XM_884524 MAS-related GPR, member B13 (Mrgprb1) -2.0 NS NS 
      
Translation NM_011710 Tryptophanyl-tRNA synthetase  (Wars) 6.6 6.9 12.6 
 NM_011163 Eukaryotic translation initiation factor 2-alpha 
kinase (Eif2ak2) 
5.4 5.0 4.6 
 NM_027350 Asparaginyl-tRNA synthetase  (Nars) 2.7 2.2 2.1 
 NM_025936 Arginyl-tRNA synthetase (Rars) 2.5 NS NS 
 NM_146217 Alanyl-tRNA synthetase (Aars) 2.5 2.2 NS 
 NM_008214 Histidyl-tRNA synthetase (Hars) 2.2 2.0 2.3 
 NM_133916 Eukaryotic translation initiation factor 3, subunit B 
(Eif3b) 
2.2 2.0 NS 
 NM_029735 Glutamyl-prolyl-tRNA synthetase (Eprs) 2.1 NS NS 
 ENSMUST0
0000055731 
Eukaryotic translation initiation factor 5A-lik (Eif5) 2.7 2.5 2.4 
 NM_148945 Ribosomal protein S6 kinase polypeptide 3 (Rps6) 2.1 2.0 2.3 
 NM_207523 Ribosomal protein L23a (Rpl23) -2.0 NS NS 
 AF260271 Ribosomal protein  L9 (Rpl9) -2.0 NS NS 
 NM_001031
808 
Ribosomal protein L41 (Rpl41) -2.0 NS NS 
 NM_007990 Finkel-Biskis-Reilly murine sarcoma virus (Fau) -2.0 NS NS 
 NM_080636 Histidyl-tRNA synthetase 2, mitochondrial 
(putative) (HARS2) 
-2.0 NS NS 
 NM_011300 Ribosomal protein S7 (Rps7) -2.0 NS NS 
 NM_016959 Ribosomal protein S3 (Rps3) -2.1 -2.0 NS 
 BC086914 Ribosomal protein l36 (Rpl36) -2.1 -2.0 NS 
 NM_009091 Ribosomal protein L15 (Rps15) -2.1 -2.0 NS 
 NM_009076 Ribosomal protein L12 (Rpl12) -2.1 NS NS 
 NM_011029 Ribosomal protein SA (Rpsa) -2.1 NS NS 
 BC082284 Ribosomal protein L27 (Rpl27) -2.1 NS NS 
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 NM_001039
534 
Phosphoseryl-tRNA kinase (Pstk) -2.1 -2.2 -2.1 
 NM_009079 Ribosomal protein L22 (Rpl22) -2.1 -2.0 NS 
 NM_011029 Ribosomal protein SA (Rpsa) -2.1 NS NS 
 BC082284 Ribosomal protein L27 (Rpl27) -2.1 NS NS 
 NM_001039
534 
Phosphoseryl-tRNA kinase (Pstk) -2.1 -2.2 -2.1 
 NM_016844 Ribosomal protein S28 (Rps28) -2.1 NS NS 
 NM_053159 Mitochondrial ribosomal protein L3 (Mrpl3) -2.1 -2.5 -2.1 
 NM_175004 Peptidyl-tRNA hydrolase 2 (Ptrh2) -2.1 -2.0 NS 
 BC096413 Ribosomal protein L37A (Rpl37a) -2.2 NS -NS 
 BC096413 Ribosomal protein L37 (Rpl37) -2.2 NS NS 
 NM_011291 Ribosomal protein L7 (Rpl7) -2.2 NS NS 
 NM_001033
865 
Ribosomal protein S27 (Rps27) -2.2 -2.3 NS 
 NM_001033
865 
Ribosomal protein S27A (Rps27a) -2.2 -2.3 NS 
 NM_016980 Ribosomal protein L5 (Rpl5) -2.3 -2.1 -2.1 
 NM_001005
859 
Ribosomal protein  L34 (Rpl34) -2.3 -2.0 NS 
      
Transcription NM_172648 Interferon activated gene 205 (Ifi205) 26.4 21.8 21.4 
 NM_016850 Interferon regulatory factor 7 (Irf7) 18.2 19.7 15.5 
 NM_008329 Interferon activated gene 204 (Ifi204) 9.7 8.4 8.4 
 NM_009283 Signal transducer and activator of transcription 1 
(Stat1) 
9.2 9.3 8.3 
 NM_008390 Interferon regulatory factor 1 (Irf1) 8.3 7.6 7.7 
 NM_010118 Early growth response 2 (Egr2) 7.3 3.0 2.6 
 NM_010751 MAX dimerization protein 1 (Mxd1) 6.6 4.4 2.4 
 NM_019963 Signal transducer and activator of transcription 2 
(Stat2) 
4.5 4.7 3.1 
 NM_009504 Vitamin D receptor  (Vdr) 4.4 2.2 2.3 
 NM_028083 Chromatin assembly factor 1 (Chaf1b) 4.3 3.3 3.4 
 NM_010931 Ubiquitin-like, containing PHD and RING finger 
domains, 1 (Uhrf) 
4.1 3.6 2.3 
 NM_010431 Hypoxia inducible factor 1, alpha subunit (Hif1a) 3.8 2.9 2.1 
 NM_008234 Helicase, lymphoid specific (Hells) 3.7 3.7 3.1 
 NM_019507 T-box 21 (Tbx21) 3.5 5.6 5.7 
 NM_025866 Cell division cycle associated 7  (Cdca7) 3.4 2.0 NS 
 NM_021878 J umonji, AT rich interactive domain 2 (Jarid2) 3.4 3.1 2.6 
 NM_007829 Fas death domain-associated protein (Daxx) 3.2 2.8 2.2 
 NM_024184 Anti-silencing function 1 homolog B (S. 
cerevisiae) (Asf1b) 
3.1 3.9 3.6 
 NM_008320 Interferon regulatory factor 8 (Irf8) 3.1 3.7 3.5 
 ENSMUST0
0000039876 
MYC binding protein 2 (Mycbp2) 3.0 2.6 2.7 
 NM_008566 Minichromosome maintenance deficient 5 (Mcm5) 2.9 3.0 2.7 
 NM_023598 AT rich interactive domain 5B  (Arid5b) 2.9 2.5 2.2 
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 NM_011119 Proliferation-associated 2G4 (Pa2g4) 2.8 2.1 NS 
 NM_021326 Nucleolar and spindle associated protein 1 (Sap30l) -2.0 NS NS 
 NM_175770 cAMP responsive element binding protein 3-like 1 
(Creb3l1) 
-2.0 -2.3 -2.0 
 NM_011957 TAF10 RNA polymerase II, TATA box binding 
protein (Taf10) 
-2.0 NS NS 
 NM_007970 Histone deacetylase 5 (Hdac5) -2.0 NS NS 
 NM_020024 Myocyte enhancer factor 2D (Mef2d) -2.0 -2.3 NS 
 NM_001077
696 
Putative homeodomain transcription factor 2 
(Phtf2) 
-2.0 NS NS 
 NM_133665 AT rich interactive domain 4B (RBP1-like) 
(Arid4b) 
-2.0 NS NS 
 NM_172992 HOP homeobox  (Hopx) -2.0 NS NS 
 NM_194262 Zinc finger protein 110 (Zfp110) -2.0 NS NS 
 NM_175606 Zinc finger protein 161 (Zfp161) -2.0 NS NS 
 NM_022981 Polymerase I and transcript release factor (Ptrf) -2.1 NS NS 
 NM_009547 Zinc finger protein 606 (Zfp606) -2.1 -2.2 NS 
 NM_008986 Zinc finger protein 809 (Zfp809) -2.1 -2.2 -2.0 
 NM_026112 IKAROS family zinc finger 3 (Ikzf3) -2.1 -2.2 NS 
 NM_011771 Zinc finger protein 273 (Zfp273) -2.1 NS NS 
 NM_175009 Transcription factor A, mitochondrial (Tfam) -2.1 NS NS 
 NM_198322 Zinc finger protein 740 (Zfp740) -2.1 NS NS 
 NM_009360 CCAAT/enhancer binding protein zeta (Cebpz) -2.1 NS NS 
 NM_153194 Mortality factor 4 like 1 (Morf4l1) -2.1 NS NS 
 NM_001024
806 
Polymerase (RNA) II (DNA directed) polypeptide 
K (Polr2k) 
-2.1 NS NS 
      
Transport NM_008491 Lipocalin 2 (Lcn2) 24.1 8.7 7.1 
 NM_023044 Solute carrier family 15, member 3 (Slc15a3) 12.9 9.9 7.2 
 NM_011990 Solute carrier family 7 (Slc7a11) 11.6 2.9 0.0 
 NM_013683 Transporter 1 (Tap1) 9.6 10.4 9.0 
 NM_054098 STEAP family member 4  (Steap4) 7.6 5.1 2.5 
 NM_016917 Solute carrier family 40 (iron-regulated transporter) 
(Slc40a1) 
6.9 3.9 2.5 
 NM_011400 Solute carrier family 2 (facilitated glucose 
transporter) (Slc2a1) 
6.0 4.3 3.5 
 NM_011400 Solute carrier family 16 (Slc16a3) 6.0 4.3 3.5 
 NM_023908 Solute carrier organic anion transporter family 
(Slco3a1) 
5.9 6.3 6.0 
 NM_011227 RAB20, member RAS oncogene family (Rab20) 5.7 3.9 2.6 
 NM_009721 ATPase, Na+/K+ transporting, beta 1 polypeptide 
(Atp1b1) 
5.3 6.7 6.9 
 NM_053108 Glutaredoxin (Glrx) 4.9 3.3 3.0 
 NM_015774 ERO1-like (Ero1I) 4.3 3.4 2.2 
 NM_016972 Solute carrier family 7 (Slc7a8) 4.2 3.9 3.5 
 NM_172621 Chloride intracellular channel 5 (Clic5) 4.2 4.3 4.9 
 NM_172621 Nucleoporin 93 (Nup93) 4.2 4.3 4.9 
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Gene Name (Gene symbol) Fold Change in Transcription 
vs. NEG mice 
   GT1            PTG          CTG 
 NM_213616 ATPase, Ca++ transporting, plasma membrane 4 
(Atp2b4) 
4.0 5.4 4.3 
 NM_011930 Chloride channel 7 (Clcn7) 4.0 4.9 3.7 
 NM_013885 Chloride channel 7 (Clic4) 3.6 3.1 2.6 
 NM_011530 Transporter 2 (Tap2) 3.3 3.6 2.9 
 NM_024281 Ribosome binding protein 1 (Rrbp1) 3.3 2.7 2.4 
 NM_009729 ATPase, H+ transporting  (Atp6vOc) 3.1 2.7 2.7 
 NM_010688 LIM and SH3 protein 1 (Lasp1) 3.1 2.9 3.4 
 NM_011404 Solute carrier family 7 (Slc7a5) 3.1 2.1 NS 
 NM_026331 Solute carrier family 25, member 37 (Slc25a37) -2.0 2.0 NS 
 NM_178746 Solute carrier family 38, member 9 (Slc38a9) -2.0 2.0 NS 
 ENSMUST0
0000066921 
Solute carrier family 25, member 40  (Slc25a40) -2.0 -2.1 NS 
 ENSMUST0
0000036862 
Component of oligomeric golgi complex 5 (Cog5) -2.0 NS NS 
 NM_011895 Solute carrier family335, member 1  (Slc35a1) -2.1 NS NS 
 NM_030057 Trafficking protein particle complex 6B 
(Trappc6b) 
-2.1 NS NS 
 NM_023202 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex (Ndufa7) 
-2.1 -2.1 NS 
 NM_133891 Solute carrier family 44, member 1  (Slc44a1) -2.2 -2.0 NS 
 NM_153163 Ca2+-dependent activator protein for secretion 2 
(Cadps2) 
-2.2 -2.7 
 
NS 
 NM_008771 Purinergic receptor P2X, ligand-gated ion channel 
(P2rx1) 
-2.2 -2.8 -2.1 
 NM_053198 Sideroflexin 4 (Sfxn4) -2.3 -2.2 -2.3 
 NM_026684 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex (Ndufb10) 
-2.3 -2.7 NS 
 ENSMUST0
0000082411 
NADH dehydrogenase subunit 3 (ND3) -2.3 NS NS 
 ENSMUST0
0000082419 
NADH dehydrogenase subunit 6 (ND6) -2.3 NS NS 
 NM_001111 Cmah -2.4 -2.5 NS 
 BC002089 Sec61 beta subunit  (SEC61b) -2.4 -2.5 -2.9 
 ENSMUST0
0000100262 
Solute carrier family 38, member 1 ( Slc38a1) -2.4 -2.2 -2.1 
 NM_020258 Solute carrier family 37, member 2 (SLC37a2) -2.5 NS -2.0 
 NM_138756 Solute carrier family 25, member 36 (Slc25a36) -2.5 -2.6 -2.7 
 NM_026693 Gamma-aminobutyric acid (GABA-A) receptor-
associated protein (Gabarapl2) 
-2.5 -2.0 NS 
 NM_013790 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 5 (Abcc5) 
-2.5 -2.2 NS 
 NM_147218 ATP-binding cassette, sub-family A (ABC1), 
member 6 (Abca6) 
-2.6 -2.6 -3.0 
 NM_025571 Mitochondria-associated protein involved in 
granulocyte (Magmas) 
-2.6 -2.8 -3.3 
 NM_011515 Vesicle-associated membrane protein 7 (Vamp7) -2.7 -2.5 NS 
 NM_026879 Chromatin modifying protein 2B (Chmp2b) -2.7 -2.4 NS 
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vs. NEG mice 
   GT1            PTG          CTG 
Apoptosis NM_009909 Interleukin 8 receptor, beta (Il8rb) 26.1 15.3 6.5 
 NM_010370 Granzyme A (Gzma) 24.8 41.2 34.5 
 NM_013542 Granzyme B (Gzmb) 21.9 49.8 16.0 
 NM_001001
495 
TNFAIP3 interacting protein 3 (Tnfaip3) 8.3 4.8 5.0 
 NM_008655 Growth arrest and DNA-damage-inducible 45 beta 
(Gadd45b) 
6.5 3.3 2.2 
 NM_007523 BCL2-antagonist/killer 1 (Bak1) 4.5 4.6 5.3 
 NM_001037
713 
XIAP associated factor 1 (Xaf1) 4.4 3.7 3.0 
 NM_007611 Caspase 7 (Casp7) 4.1 3.4 3.3 
 NM_019955 Receptor-interacting serine-threonine kinase 3 
(Ripk3) 
3.9 3.9 5.7 
 NM_007987 Fas ligand  (Fas) 3.5 2.5 2.1 
 BC046640 Transmembrane protein 173(Tmem173) 3.4 3.2 3.5 
 NM_009773 Budding uninhibited by benzimidazoles 1 
homolog, beta (Bub1b) 
3.4 3.6 3.6 
 NM_197889 Interferon zeta (Ifnz) 3.2 3.8 NS 
 NM_007829 Fas death domain-associated protein (Daxx) 3.2 2.8 2.2 
 NM_011817 Growth arrest and DNA-damage-inducible 45 
gamma (Gadd45g) 
3.0 3.9 3.0 
 NM_026669 Transmembrane BAX inhibitor motif containing 6 
(Tmbim6) 
3.0 2.9 3.0 
 NM_009425 Tumor necrosis factor (ligand) superfamily, 
member 10 (Tnfsf10) 
3.0 4.2 4.1 
 NM_010177 Fas ligand (Fasl) 3.0 3.9 4.4 
 NM_145827 NLR family, pyrin domain containing 3 (NLrp3) 2.9 2.0 NS 
 NM_010019 Death-associated protein kinase 2 (Dapk2) 2.7 3.3 3.5 
 NM_009760 BCL2/adenovirus E1B interacting protein 3 
(Bnip3) 
2.5 NS NS 
 BC092213 Cytochrome c, somatic (Cycs) 2.5 2.6 2.6 
 NM_009402 Peptidoglycan recognition protein 1(Pglyrp1) 2.4 2.1 2.2 
 NM_009742 B-cell leukemia/lymphoma 2 related protein A1a 
(Bcl2a1a) 
2.4 NS NS 
 NM_009743 BCL2-like 1 (Bcl2l1) 2.4 2.3 2.1 
 NM_207680 BCL2-like 11 (Bcl2l11) 2.3 2.1 2.1 
 NM_001040
654 
Cyclin-dependent kinase inhibitor 2A (Cdkn2a) -2.2 -2.2 -2.1 
 NM_008771 Purinergic receptor P2X (P2rx1) -2.2 -2.8 -2.1 
 NM_144931 NEDD8 activating enzyme E1 subunit 1 (Nae1) -2.3 -2.4 NS 
 NM_010872 NLR family, apoptosis inhibitory protein 2 (Naip2) -2.3 -2.1 NS 
 BC059254 PH domain and leucine rich repeat protein 
phosphatase (Phlpp) 
-2.3 NS NS 
 NM_008612 Menage a trois 1 (Mnat1) -2.4 NS NS 
 NM_007465 Baculoviral IAP repeat-containing 2 (Birc2) -2.5 -2.2 -2.5 
 NM_020558 TBC1 domain family, member 2B (C1d) -2.7 -2.1 NS 
 NM_021897 Transformation related protein 53 inducible nuclear 
protein (Trp53inp1) 
-2.7 -2.2 NS 
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 NM_019745 Programmed cell death 10 (Pdcd10) -2.8 -3.1 NS 
 NM_134131 Tumor necrosis factor, alpha-induced protein 8 
(Tnfaip8) 
-2.8 -3.0 -2.1 
 NM_010121 Eukaryotic translation initiation factor 2 alpha 
kinase (Eif2ak3) 
-2.8 -2.2 NS 
 NM_010241 Thymoma viral proto-oncogene 1 interacting 
protein (Aktip) 
-2.8 -2.7 -2.0 
 NM_008160 Glutathione peroxidase 1(Gpx1) -3.0 NS NS 
 NM_144792 Sphingomyelin synthase 1(Sgms1) -3.1 -2.9 NS 
 NM_030750 Sphingosine-1-phosphate phosphatase 1(Sgpp1) -3.1 -2.5 NS 
 NM_008580 Mitogen-activated protein kinase kinase kinase 5 
(Map3k5) 
-3.2 -2.8 -2.2 
 NM_029653 Death associated protein kinase 1(Dapk1) -3.8 -3.8 NS 
 NM_008670 NLR family, apoptosis inhibitory protein 1 (naip1) -3.9 -3.5 NS 
 ENSMUST0
0000027373 
Protein phosphatase 1F (Ppm1f) -4.0 -3.3 -3.3 
 NM_010871 Baculoviral IAP repeat-containing 1f (Birc1f) -4.1 -3.1 NS 
 NM_010870 NLR family, apoptosis inhibitory protein 5 (Naip5) -4.6 -3.6 -2.2 
 NM_146042 Ring finger protein 144B (Rnf144b) -4.8 -5.9 -4.1 
 NM_011050 Programmed cell death 4 (Pdcd4) -7.4 -5.6 -2.9 
 NM_010258 GATA binding protein 6 (Gata6) -7.8 -7.9 -2.7 
 NM_009690 CD5 antigen-like (Cd51) -19.0 -2.2 4.3 
      
Cell Cycle NM_009828 Cyclin A2 (Ccna2) 5.9 6.4 5.7 
 NM_001037
713 
XIAP associated factor 1 (Xaf1) 4.4 3.7 3.0 
 BC085238 Cyclin B1(CCnb1) 4.4 6.0 4.8 
 NM_028083 Chromatin assembly factor 1, subunit B (p60) 
(Chaf1b) 
4.3 3.3 3.4 
 NM_145150 Protein regulator of cytokinesis 1(Prc1) 4.2 5.6 5.0 
 NM_010615 Kinesin family member 11 (Kif11) 4.0 4.9 3.8 
 NM_008563 Minichromosome maintenance deficient 3 (Mcm3) 4.0 3.8 2.7 
 NM_027954 Synaptonemal complex central element protein 2 
(Syce2) 
3.9 2.5 2.6 
 NM_008564 Minichromosome maintenance deficient 2 mitotin 
(Mcm2) 
3.8 3.1 2.6 
 NM_008234 Helicase, lymphoid specific (Hells) 3.7 3.7 3.1 
 NM_001113
179 
Budding uninhibited by benzimidazoles 1 homolog 
(Bub1) 
3.6 4.6 4.1 
 NM_133762 Non-SMC condensin II complex, subunit G2 
(Ncapg2) 
3.6 5.2 4.4 
 NM_009773 Budding uninhibited by benzimidazoles 1 homolog 
(Bub1b) 
3.4 3.6 3.6 
 NM_007669 Cyclin-dependent kinase inhibitor 1A (Cdkn1) 3.4 3.0 3.3 
 NM_144553 Discs, large (Drosophila) homolog-associated 
protein 5 (Dlgap5) 
3.2 3.5 3.2 
 NM_009829 Ubiquitin-like, containing PHD and RING finger 
domains, 1 (Uhrf1) 
3.2 2.7 2.4 
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 NM_009829 Cyclin D2 (CCnd2) 3.2 2.7 2.4 
 NM_028760 Centrosomal protein 55 (Cep55) 3.0 3.6 3.6 
 NM_010892 NIMA (never in mitosis gene a)-related expressed 
kinase 2 (Nek2) 
3.0 3.4 3.0 
 NM_175155 SAM and SH3 domain containing 1 (Sash1) 2.9 3.1 2.9 
 NM_144818 Non-SMC condensin I complex, subunit H (Ncaph) 2.8 3.2 3.1 
 NM_001025
577 
Avian musculoaponeurotic fibrosarcoma (Maf) 2.7 2.0 NS 
 NM_175155 SAM and SH3 domain containing 1 (Sash1) 2.9 3.1 2.9 
 NM_144818 Non-SMC condensin I complex, subunit H (Ncaph) 2.8 3.2 3.1 
 NM_001025
577 
Avian musculoaponeurotic fibrosarcoma (Maf) 2.7 2.0 NS 
 NM_133851 Nucleolar and spindle associated protein 1 
(Nusap1) 
2.7 3.0 3.8 
 NM_011497 Aurora kinase A (Aurka) 2.6 3.0 3.1 
 NM_001083
188 
Ligase I (Lig I) 2.6 2.8 2.6 
 NM_026560 Cell division cycle associated 8 (Cdca8) 2.6 2.8 3.0 
 NM_009828 Cyclin A2 (Ccna2) 5.9 6.4 5.7 
 NM_008885 Peripheral myelin protein 22 (Pmp22 ) -8.4 -5.9 NS 
 NM_011050 Programmed cell death 4 (Pdcd4) -7.4 -5.6 -2.9 
 NM_007964 Ecotropic viral integration site 5(Evi5) -7.0 -6.1 -3.3 
 NM_181394 Anaphase promoting complex subunit 13 
(Anapc13) 
-4.5 -3.4 -2.5 
 NM_001081
222 
Establishment of cohesion 1 homolog 1 (Esco1) -3.4 -2.8 NS 
 NM_026902 Malignant T cell amplified sequence 1 (Mcts1) -3.1 -2.9 -2.0 
 NM_019405 Centrin 2 (Cetn2) -3.0 -2.6 NS 
 NM_178667 Transcription factor Dp 2 (Tfdp2) -2.9 -2.5 NS 
 NM_001024
622 
PEST proteolytic signal containing nuclear protein 
(Pcnp) 
-2.8 -2.1 -2.1 
 NM_009826 RB1-inducible coiled-coil 1 (Rb1cc1) -2.7 -2.4 NS 
 NM_007635 Cyclin G2 (Ccng2) -2.6 -2.3 NS 
 NM_007635 Wilms' tumour 1-associating protein (Wtap) -2.6 -2.3 NS 
 NM_145541 RAS-related protein-1a  (Rap1a) -2.5 -2.4 -2.0 
 NM_008612 Menage a trois 1 (Mnat1) -2.4 -1.9 NS 
 NM_026832 Cell growth regulator with ring finger domain 1 
(Cgrrf1) 
-2.3 -2.0 NS 
 NM_144931 NEDD8 activating enzyme E1 subunit 1 (Nae1) -2.3 -2.4 NS 
 NM_009875 Cyclin-dependent kinase inhibitor 1B (Cdkn1b) -2.2 NS NS 
 NM_183186 Forkhead box N3 (Foxn3) -2.2 NS NS 
 NM_001040
654 
Cyclin-dependent kinase inhibitor 2A (Cdkn2a) -2.2 -2.2 -2.1 
 NM_001114
328 
Cell cycle progression 1 (Ccpg1) -2.2 -2.1 NS 
 NM_007631 Cyclin D1 (Ccnd1) -2.1 -2.1 NS 
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   GT1 PTG CTG 
 AB041558 Myeloid/lymphoid or mixed-lineage leukemia 5 
(Mll5) 
-2.1 NS NS 
 NM_025389 Anaphase promoting complex subunit 11 
(Anapc11) 
-2.1 NS NS 
 NM_001031
808 
Mitochondrial ribosomal protein L41 (Mrpl41) -2.0 NS NS 
Table 3-5. T. gondii microarray experiment was carried out as previously described above. Altered 
transcripts are categorized based on functional group. Genes listed correspond to gene profiles shown in 
Figure 6 A-I.  Values represent fold change differences in signal intensity levels compared to NEG 
samples. Genes were considered induced if significantly up regulated, ≥ 2 fold and repressed if 
significantly down regulated, ≤ -2 fold. NS indicates not significantly expressed, italicized font indicates 
induced genes and normal font indicates repressed genes. All values are significant at p ≤ .05.  
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Uninfected cells served as control (Figure 3-5.J-L). Bar graphs show percent expression of 
duplicate samples stained for each treatment (Figure 3-5)   
Discussion 
In this study, we examined gene expression in mice infected with three distinct T. gondii 
strains. These data suggest that even though virulent, intermediately virulent and non-virulent 
strains elicit an overall similar pattern of response in mice, there are specific differences of host 
gene expressions from the infection of the three genetically different T. gondii strains. Day 5 post 
infection was selected for microarray analysis based on the tissue burden assay (Figure. 2-2). It is 
likely that at day 5 post infection, significant shifts in host response to infection occur and Type 
II and III strains start to switch from tachyzoite to bradyzoite growth. It is shown that Type I 
strain reached significantly higher spleen tissue burden compared to that of Type II and III 
strains which had comparable parasite loads (Figure. 3-3). Using the genes highly upregulated or 
downregulated, RT-PCR confirmed our microarray and trends in gene expression were 
comparable. Oddly, those genes that were mildly upregulated during non virulent infection were 
suppressed in our RTPCR data (Table 3-3). One possible explanation could be that the low 
parasite numbers during non virulent infection could significantly change the ratio of host cells 
present and sampled. Interestingly, gene expression results showed that Type I and II 
consistently induced similar trends of gene expression among biological processes with the latter 
having slightly lower levels, while Type III response was much lower (Figure. 3-2 A-I). In 
addition, both Type I and II strains caused a strong polarized effect on host gene expression, in 
that host genes were either highly induced or more suppressed than that by Type III strain. These 
results are surprising, as mouse infections with Toxoplasma Type II and III strains result in 
parasite persistence that is associated with cyst formation and chronic infection within the hosts, 
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and it was expected that Type II and III would share more similarities in affecting gene 
expressing in mice, not that of the Type I and II strains. These results suggest parasite genetic 
background play an important role in host response. A recent study characterizing the strain 
specific host cell response to T. gondii using neuroepithelial cells showed that Type I strain 
caused a wide transcriptional response encompassing > 1,000 genes, while cells infected with 
Type II and III strains results in the alteration of 78 and 344 genes, respectively (Xiao J, 2010). 
This study suggests that Type II elicits a weaker response to infection in contrast to Type III. 
This conclusion is quite different from results observed in our present study. These differences 
are possibly attributed to the human neuroepithelial cells used in the above mentioned study 
versus the diverse cell types present in peritoneal lavage of mice collected during our study.  
The cells responsible for gene expression during T. gondii infection in our study were 
monitored. FACS analysis showed that there is no significant difference between macrophages 
and dendritic cells among all three treatments (Figure 3-4 and Figure 3-5). Interestingly, percent 
of neutrophils expressed only differ among virulent GT1 and non virulent CTG infection. Taken 
together, gene expression profiles obtained from in vivo infections are not influenced by specific 
cells but expression is based on parasite genotype.  Due to the inadequate replications and 
shortcomings of experimental design, further conclusions could not be made.  
An overactive host immune response has been shown in mice infected with T. gondii 
virulent strains compared to infection with non virulent strains. This over reaction of Th1 
proinflammatory response plays a significant part to mortality in mice infected with virulent 
Type I strain (Mordue, 2001). We expected that genes related to the immune response group 
would have higher expression levels during virulent T. gondii infection compared to intermediate 
and non virulent infection. Analysis of genes belonging to functional groups of immune and 
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inflammatory responses showed that genes highly expressed were cytokines, chemokines and 
upstream factors responsible for induction of proinflammatory response (CCL22, CCL17, 
CCL12, CCL7 and CCL2) (Table 3-5 ). In addition, NOS, Myd88 and TNF were up-regulated in 
all three types of infections. Compared to uninfected mice, NOS was 13 and 12 fold higher in 
Type I and II infection, respectively. In contrast, this same gene was only 4 fold higher during 
Type III infection. Myd88 was up-regulated 4 fold in both Types I and II while up-regulated by 
2.4 fold in Type III infection. Lastly TNF was up-regulated ~5 fold during Type I and II 
infections and up-regulated at a lower level (3 fold) during Type III infection (Table 3-5). IL-27 
was significantly expressed (3 fold higher) during all T. gondii infection compared to uninfected 
mice. This cytokine has been shown to regulate T helper cell response during parasite infection, 
regulating the expansion of the Th1 response (15). Taken together, expression profiles based on 
biological processes showed that Type I infection modulated a larger number of gene expression 
in mice, closely followed by the Type II infection, and Type III infection had the least effect on 
mice. The proinflammatory cytokines induced during T. gondii infection may serve as an 
important mediator for defense, but due to the uncontrolled response when infected with the 
Type I strain, more damage is caused to the host. 
 Macrophages are among the immune cells recruited and activated upon infection with T. 
gondii (Denkers, 2003). Our results showed an increased suppression of a macrophage receptor 
gene (MARCO) in those mice infected with the non virulent strain. This same gene was 
suppressed during Type I and II strain infection when compared to negative control mice 
(TABLE 3-3). MARCO has been shown to play a role in determining infection outcome in mice 
infected with Leshmania major. Gomes et al showed that MARCO expression increased in 
spleens of mice infected with L. major compared to saline injected mice (negative control) 
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leading to increased uptake of parasite, which eventually neutralized the infection (Gome, 2009) 
This phenomenon may suggest that the Type I and II T. gondii strains may be more efficiently 
internalized by macrophages than that of the Type III strain. Another interesting finding was the 
enhanced suppression of proteoglycan 4 (Prg4) with Type I infection. Prg4 expression was 
suppressed by 139.5, 86.7 and 1.9 folds in Type I, II and III T. gondii strains, respectively. Prg4 
functions in lubrication and cytoprotection in the synovial fluid. The protein has large mucin-like 
repeats which, substituted with O-linked oligosaccharides, impart lubricating and cytoprotective 
properties (Ikegawa, 2000). However, the role of Prg4 in T. gondii infection is not clear. 
Two serine protease inhibitors (Serpinb2 and Serpinb10) were also highly suppressed in 
mice infected with the Type I and II T. gondii strains. Serpinb2 was suppressed by 61.4, 31.7 and 
1.4 folds in Type I, II and III infection, respectively. While Serpinb10 was suppressed by 83.5, 
94.2 and 6.7 folds in Types I, II and III, respectively. It was suggested that SERPINs could 
inhibit host cell apoptosis (Ahn, 2009). Some SERPINs have been shown to inhibit cathespins 
and lysosomal enzymes. A previous study showed that, when T. gondii serine protease activity 
was inhibited via two serine protease inhibitor 3,4-dichloroisocoumarin and 4-(2-aminoethyl)-
benzenesulfonyl fluoride, the parasite was unable to successfully invade host cells (Conseil, 
1999). When T. gondii was treated with chymotrypsin-like serine protease inhibitors Z-Gly-Gly-
Phe-CMK and TPCK, its replication was inhibited and the viability decreased (Shaw, 2002). 
Lagal et al showed that when TgSUB1 (a serine protease secreted from microneme) was 
disrupted, T. gondii showed decreased attachment and invasion (Lagal, 2010). It has been 
reported that ROP18, a serine protease, is highly expressed in Type I T. gondii strains and is 
responsible for acute virulence in mice (Taylor, 2006). Taken together, these data demonstrate 
that proteases are important for survival and transmission of T. gondii. Suppression of host 
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protease inhibitors maybe an offensive mechanism developed by highly virulent T. gondii 
strains. This current study indicated that Type I T. gondii strain had the strongest effect to up- or 
down regulate mouse gene expression, closely followed by the Type II strain, whereas Type III 
strain had mild effect on mouse gene expression. As reported in previous study, over reaction of 
Th1 pro-inflammatory response was associated with the death of mice infected with Type I strain 
(Mordue, 2001). In the perspective of evolution, Type II strain may have the adaptive advantage 
over Type I and III strains. It is likely that high virulence of Type I strain may kill its mouse host 
quickly, posing a negative impact to parasite transmission. Though both Type II and III strains 
can readily establish chronic infection in mice, our current study showed that the former can 
induce much stronger immune and inflammatory responses than the latter. This may allow Type 
II strain to out compete Type III strain in the context of within-host competition using host 
immune and inflammatory responses to exclude the competitor. This may explain the dominance 
of Type II lineage worldwide (Ajzenberg, 2002; Howe, 1995). Though there is no direct 
evidence to support this hypothesis, it is possible to test it experimentally in future studies. In this 
study we showed that distinct parasite strains caused different responses in its host. The 
differential host-parasite interaction may ultimately dictate the pathogenesis of T.gondii 
infection. Future work should be aimed towards identifying genetic regulators in the host to 
understand the mechanisms of T. gondii pathogenesis. 
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CHAPTER IV.  FUTURE DIRECTIONS 
 
Introduction 
 
 In this dissertation, research confirming parasite replication in tissue among distinct T. 
gondii strains and the effect parasite genetic background has on host gene expression are 
presented.  Here, we show that uncontrolled growth is a common feature of all virulent strains.. 
In addition, it is shown that Type I and II have similar expression profiles during acute infection 
while Type III elicits a decreased response in mice.  Taken together, understanding both parasite 
and host gene expression during infection could lead to the identification of key elements 
involved in T. gondii virulence and resistance in host.  
Identification of Mechanisms of Host Resistance 
In my work presented in Chapter III, microarray data identified several host defense 
genes that were significantly suppressed by virulent T. gondii GT1 strain. To elucidate the role of 
these genes in the pathogenesis of T. gondii infection, further studies are needed. The use of gene 
specific knock out mice would provide mechanistic insight of the roles of these genes. For 
example, serine protease inhibitors (Serpinb2, Serpinb10), were significantly repressed during 
Type I and II in vivo infection. Using knockout mice, we could monitor this protein‟s role in 
protection and pathogenesis. Genetically engineered knock out mice could also answer a critical 
question in the field about whether the numerous Toxoplasma regulated host transcription factors 
identified using in vitro experimental systems are actually activated in vivo. These types of 
experiments would add biological and mechanistic significance to our microarray data.  
In addition, we can use mice of different genetic backgrounds to identify the role that 
host genetics play on host resistance. Using C57Bl/6 and DBA/2 mice, the former are resistant, 
while the latter are susceptilble to T. gondii infection, we can study a population of progeny from 
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genetic crossing of these two inbred strains to study gene expression network and pathways.. 
Taking advantage of the in vivo methods and microarray technology described in this 
dissertation we can infect the progeny with the Type I virulent strain and perform microarray 
analysis to observe alterations in gene expression. Using expression quantative trait loci 
mapping, we can identify the genomic loci responsible for expression of thousands of genes. 
Ultimately, we can characterize candidate genes by genetic knockout mice experiments.  
Comparison of T. gondii gene expression profiles during in vivo infection 
 By and large, the original goal of this project was to identify upstream genetic elements 
that regulate virulence in T. gondii and confer resistance in host.  Experiments using microarray 
technology to elucidate genetic factors regulating virulence in T. gondii presented technical 
difficulties. Due the uncontrolled growth phenotype characteristic of virulent strains, gene 
expression comparison to non virulent strains becomes inaccurate. In order to overcome this feat, 
we can increase inoculum dose of parasite in mice. Preliminary results testing this method, 
proved that indeed parasite concentration was increased. The consequence of increasing the 
parasite concentration had major effects on gene expression profiles, therefore limited 
conclusions could be made. Moving forward, we will optimize inoculum dose needed to obtain 
accurate conclusions. Taking advantage of the alternative method for determining virulence 
described in chapter II, we can confirm optimal infectious dose by comparing parasite load ratios 
between Type I and III strains in peritoneal lavage. Results from this study will lay framework 
for identification of key genes controlling virulence in T. gondii.  
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Appendix I is a collection of three co-authored publications.  
 
1. Dubey JP, Applewhaite L, Sundar N, Velmurugan GV, Bandini LA, Kwok, C.H, Hill, R, 
Su C. 2007. Molecular and biological characterization of Toxoplasma gondii isolates from free-
range chickens from Guyana, South America identified several unique and common parasite 
genotypes. Parasitology. 134:1559-1565 
 
 The prevalence of Toxoplasma gondii in free-ranging chickens (Gallus domesticus) is a good 
indicator of the prevalence of T. gondii oocysts in the soil because chickens feed from the 
ground. The prevalence of T. gondii in 76 free-range chickens from Guyana, South America was 
determined. Antibodies to T. gondii were assayed by the modified agglutination test (MAT), and 
found in 50 (65.8%) of 76 chickens with titres of 1 : 5 in four, 1 : 10 in one, 1 : 20 in five, 1 : 40 
in seven, 1 : 80 in six, 1 : 160 in eight, 1 : 320 in four, 1 : 640 or higher in 15. Hearts and brains 
of 26 chickens with titres of<1: 5 were pooled in 5 batches and bioassayed in mice. Hearts and 
brains of 50 chickens with titres of 1 : 5 or higher were bioassayed in mice. Toxoplasma gondii 
was isolated by bioassay in mice from 35 chickens with MATtitres of 1 : 20 or higher. All mice 
inoculated with tissues of 30 infected chickens remained asymptomatic. Toxoplasma gondii 
isolates from 35 chickens were genotyped using 11 PCR-RFLP markers including SAG1, SAG2, 
SAG3, BTUB, GRA6, c22-8, c29-2, L358, PK1, a new SAG2, and Apico. A total of 9 genotypes 
were identified, with 5 genotypes (nos 1, 4, 5, 6 and 7) unique to Guyana, 2 genotypes (nos 2 and 
3) previously identified in chickens from Brazil, 1 genotype (no. 8) previously identified in 
chickens from Brazil, Costa Rica and Nicaragua, and 1 genotype (no. 9) belonging to the clonal 
type III lineage that exists globally. Infection with 2 genotypes was found from 1 chicken (Table 
A1-1). This is the first report of genetic characterization of T. gondii isolates from any host from 
Guyana  
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Table A1-1. Summary of genotyping of Toxoplasma gondii isolates from chicken from Guyana 
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2. Dubey, J.P., López-Torres, H.Y.,  Sundar, N.,  Velmurugan, G.V.,  Ajzenberg, D., Kwok, 
P. CH.,  Hill, R., Dardé, M.L., and Su, C. 2007. Mouse-Virulent Toxoplasma gondii Isolated 
from Feral Cats on Mona Island, Puerto Rico. Journal of Parasitology. 93: 1365-1369 
 
Cats are essential in the life cycle of Toxoplasma gondii because they are the only hosts that can 
excrete the environmentally resistant oocysts. Samples of serum, feces, and tissues from cats 
from Mona, a remote island off the coast of Puerto Rico, were examined for T. gondii infection. 
Antibodies to T. gondii were assayed by the modified agglutination test and found in 16 of 19 
(84.2%) of cats, with titers of 1:10 in 2, 1:80 in 1, 1:160 in 4, 1:320 in 3, and 1:1,280 or higher in 
6. Tissues of 19 of the 20 cats were bioassayed in mice for T. gondii infection. Toxoplasma 
gondii was isolated from tissues of 12 cats: from the hearts of 9, skeletal muscle of 10, and brain 
of 1 cat. All infected mice from 10 of 12 isolates died of acute toxoplasmosis during primary 
infection. Genotyping of these 12 T. gondii isolates (designated (TgCatPr 1-12) by 10 multilocus 
PCR-RFLP markers, i.e., SAG1, SAG2, SAG3, BTUB, GRA6, c22-8, c29-2, L358, PK1, and an 
apicoplast marker Apico, and the 6 multilocus microsatellite markers TUB2, W35, TgM-A, B18, 
B17, and M33, revealed 7 genotypes; 5 isolates had Type I alleles at all loci except at 1 
microsatellite locus, and the remainder were atypical (Table A1-2). The latter isolates of T. 
gondii were different biologically and phenotypically from the feline isolates from the rest of the 
Americas. One isolate (TgCatPr 12) was a mixed infection with 2 genotypes. 
 
3. Dubey, J.P., Quirk, T., Pitt, J.A., Sundar, N., Velmurugan,G.V.,  Kwok, O.CH., Leclair, 
D.,  Hill, R. and Su, C. 2008. Isolation and Genetic Characterization of Toxoplasma gondii from 
Raccoons (Procyon lotor), Cats (Felis domesticus), Striped Skunk (Mephitis mephitis), Black 
Bear (Ursus americanus), And Cougar (Puma concolor) from Canada. Journal of Parasitology, 
94:42-45.  
 
Viable Toxoplasma gondii was isolated by bioassay in mice from tissues of 2 feral cats (Felis 
domesticus), 2 raccoons (Procyon lotor), a skunk (Mephitis mephitis) trapped in remote locations 
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in Manitoba, Canada, and a black bear (Ursus americanus) from Kuujjuaq, northern Quebec, 
Canada. Genotyping of these T. gondii isolates using polymorphisms at 10 nuclear markers 
including SAG1, SAG2, SAG3, BTUB, GRA6, c22-8, c29-2, L358, PK1, and an apicoplast 
marker Apico revealed 4 genotypes (Table A1-3). None of the isolates was clonal archetypal 
Types I, II, and III found in the United States. These results are in contrast with the Type II 
genotype that is widespread in domestic animals and humans throughout the United States and 
Europe. This is the first genotyping of T. gondii isolates from this part of North America.
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Table A1-3. Genotyping of Toxoplasma gondii isolates from wild cats from Canada 
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Introduction 
Previous data has suggested that T. gondii virulence may be regulated by a few key 
genetic factors (Denkers 2007, Taylor 2006, Jerome 1998). In general, our goal is to understand 
these genetic elements that may be regulating virulence among different T. gondii strains. 
Therefore, it is necessary to observe key differences in gene expression of parasite during in vivo 
infection. Due to major phenotypic differences between Type I and III clonal strains, we 
hypothesized that gene expression differences should be greater among these two lineages in 
vivo. We aimed to identify significant differences among these strains using microarray 
technology. Our results showed that due to the increased replication rate of Type I parasites, the 
RNA concentrations between strains were not at comparable levels for further analysis. Here we 
describe troubleshooting methods to enrich non virulent parasites. 
Materials and Methods 
Cell culture of parasite strains and infection in mice. Human foreskin fibroblasts (HFF) were 
grown in Dulbecco‟s modified Eagle medium (DMEM) supplemented with 10% of heat 
inactivated fetal bovine serum (Hyclone#SH30070.03 HI/IR), 1% of 100x Non Essential Amino 
Acids (NEAA-Fisher Scientific cat. no. - SH3023801), 0.4% of 1M HEPES buffer and 0.1 % of 
10 mg/ml gentamicin (Invitrogen #15710-64) and maintained in T25 vented culture flasks at 
37°C with 5% CO2. T. gondii strains GT1 (virulent) and CTG (non-virulent) were expanded and 
maintained in confluent HFF monolayer to reach consistent two-day passages prior to use for 
experiments.  
Toxoplasma gondii tachyzoites of GT1 and CTG strains were harvested by filtering 
through 3 μm pore size polycarbonate filters (Whatman cat. no. 420400) and counted. Five 
hundred tachyzoites of each of the GT1 and CTG strains were inoculated into four 6-8 week old 
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female outbred CD-1 (ICR- Harlan Sprague) mice by intraperitoneal injection (IP).For increased 
inoculum assay, mice were infected with 10
4
 of non-virulent CTG tachyzoites. At day 5 post 
infection, mice were anesthetized to the state of unconsciousness, followed by euthanization with 
cervical dislocation. Five mL of ice cold PBS was injected into peritoneal cavity and then 
peritoneal lavage was collected. Cells of peritoneal lavage were pelleted by centrifugation. 
Supernatant was removed and pellet was resuspended in 1ml RNAlater, mixed and incubated in 
4ºC for 1 hour, then stored in -70ºC until RNA extraction for microarray experiments. The 
spleens were collected from mice, weighed, homogenized and diluted in PBS to determine 
parasite load by real-time PCR (RT-PCR). 
 Microarray analysis. Total RNA was extracted from cells collected from peritoneal 
lavage of mice infected with GT1 and CTG using Qiagen RNeasy Plus Mini Kit (Qiagen cat. no. 
98 74131) following manufacturer‟s instruction. For parasite gene expression profiling, 
ToxoGeneChip array containing ~ 8000 features was used. Microarray was carried out at the 
University of Tennessee Affymetrix Core Facility. RNA samples were processed according to 
the Affymetrix Protocol for One-Cycle DNA Synthesis using a Message Amp II102 Biotin 
Enhanced Kit (Ambion PN#am1791, Austin, TX). 5 μg of fragmented cRNA was hybridized to 
the GeneChip, previously described. Arrays were washed and stained using the Affymetrix 
Hyb/Stain kit PN900720 and Affymetrix prepared wash solutions and an Affymetrix Fluidics 
450 wash station. Arrays were immediately scanned using the Affymetrix 7G scanner. Array 
images were visually inspected for anomalies. The individual chip scans were quality checked 
for the presence of control genes and background signal values. 
 Ranking Analysis. The raw data from Affycore Analysis was extracted. Transcripts were 
sorted based on signal intensity values.  
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Filtration method. HFF cells were infected with Type III VEG parasites. Parasites were 
harvested as described above. In addition, we added and additional filtration step via 3μm 
polycarbonate filter (Whatman cat no. 420400). DNA was extracted using Qiagen DNeasy Blood 
and Tissue Kit (Qiagen cat no. 69504). The number of parasites was determined by qPCR of 
extracted DNA using a TaqMan probe targeting the ITS1 sequence (GenBank Accession# 
AY143141).   The primers for PCR amplification were ITS1-Fx: 
GAAGGGGCTCAATTTCTGG and ITS1-Rx: TGTTCCTCAGATTTGTTGTTTGA, which 
amplifies a 117 bp sequence. The ITS1 probe was 5‟-/56-
FAM/CGTGTCTCTGTTGGGATACTGATTTCCAGG/3BHQ-1/-3‟, with the 5‟ end labeled 
with FAM and the 3‟ end labeled with Black Hole Quencher-1 (BHQ-1) (Integrated DNA 
Technologies, Inc.) 
Sonication method. In brief, ITS1 sequence (GenBank Accession# AY143141) was used 
to quantify parasite as described above, for parasite DNA present after sonication treatments. 
The number of host cells was determined by qPCR of extracted DNA using a TaqMan probe 
targeting the GAPDH sequence (GenBank Accession# NC_000012.11). The primers for PCR 
amplification were GAPDH- Fx: TGCACCACCAACTGCTAG and GAPDH-Rx: 
GGATGCAGGGATGATGTTC, which amplifies a 177 bp sequence. The GAPDH probe was 
5‟-/56-FAM/CAGAAGACTGTGGATGGCCCT/3BHQ-1/-3‟, with the 5‟ end labeled with FAM 
and the 3‟ end labeled with Black Hole Quencher-1 (BHQ-1) (Integrated DNA Technologies, 
Inc.). We determined the concentration of host cell (HFF) only, parasite only and host/ parasite 
combined after harvesting. Samples were sonicated at five different settings (No sonication, 
10sec for 5, 5sec for 5, 10sec for 4, 5sec for 4 and 10sec for 3). to determine optimal sonication 
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using Sonicator Heat Systems ultrasonics inc. cell disrupter. Model W220F. For parasite/ host 
combined detection parasite were grown in macrophage J77A.1 cell line. 
Results 
Our results showed that during virulent infection genes upregulated were associated with 
tachyzoite stage, host cell adherence and invasion of the parasite. These same genes were 
undetectable during non virulent infection (Fig A2-1). These results further suggest, that patterns 
of expression may be controlled by a few “master” regulators. Unfortunately, the significant 
differences among virulent and non virulent strains in vivo growth rate presented technical 
difficulties in drawing accurate conclusions from this experiment.  
In order to observe the effect increased filtration has on segregating parasite from host 
cells, we added an additional filtration step to common harvesting procedures. Our results 
showed that there was no significant difference in parasite numbers after additional filtration 
when compared to normal filtration methods (Fig A2-2).  
As a secondary troubleshooting method we employed the use of sonication to increase 
parasite RNA. In biology, sonication is often used to disrupt cell membranes and release cellular 
contents. For this reason we aimed to use this technique to release intracellular parasites in order 
to enrich total parasite RNA extracted. Results showed that regardless of sonication treatment, 
there were no significant differences in parasite concentrations (Fig A2-3).  
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Type I 
Rank Gene 
Signal 
Intensity 
1 GRA5 10476 
2 SAG1 8543 
3 GRA1 8382 
4 GRA3 7877 
5 GRA2 5038 
6 SAG2 3457 
7 MIC3 3387 
8 20K cyclophilin 2891 
9 GRA6 2660 
10 GRA7 1975 
11 MIC1 1302 
12 MIC11 1314 
13 MIC10 1251 
14 ROP18 1197 
15 Ser/Thr 
phosphatase 
1072 
Type III 
Rank Gene 
Signal 
Intensity 
1 hypothetical protein  2388 
2 hypothetical protein  577 
3 hypothetical protein  443 
4 subtilisin-like serine protease 423 
5 hypothetical protein  227 
6 hypothetical protein 234 
7 conserved hypothetical protein 171 
8 hypothetical protein 156 
9 conserved hypothetical protein  155 
10 hypothetical protein  158 
11 hypothetical protein  157 
12 hypothetical protein 142 
13 Casein Kinase I  134 
14 Conserved hypothetical protein 93 
15 hypothetical protein 97 
 
 
 
 
Figure A2-1. Parasite gene expression. CD-1 outbred mice were infected with 200 tachyzoites 
of either Type I (GT1) or Type III (CTG), sacrificed, peritoneal lavage collected and total RNA 
isolated on Day 5. Biotinylated cRNA was hybridized to cDNA microarrays and signal intensity 
values were obtained. Only genes highly ranked were selected and normalized to GAPDH 
internal control.  
   
           Virulent (GT1)                                                Non Virulent (CTG) 
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Fig A2-2. Filtration method. HFF cells were infected in vitro with Type III VEG. Harvested 
tachyzoites were either filtered under normal harvesting conditions or treated with an additional 
filtration step. P = .05.method.  
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Figure A2-3. Sonication method. HFF and RAW cell lines were grown and maintained in vitro. 
Different sonication settings were used to observe effect on cell disruption. (A) Quantification of 
HFF host cells only and parasites harvested from host cells. (B) Host/ parasite detection. 
Parasites were not harvested until after sonication of mixed (parasite/ host) cells.  
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As a last attempt to enhance parasite RNA of non virulent strain, we increased the initial 
inoculum into mice. Typically, during in vivo infections, we inoculate approximately 200 – 1000 
tachyzoites into mice. Due to the decreased levels of parasite RNA extracted from non virulent 
infected mice, we hypothesized that if we increase the initial dose, downstream parasite 
concentrations will also increase. CD-1 outbred mice were I.P. inoculated with 10
4
 Type III 
(CTG) parasites. On day 5, mice were sacrificed and peritoneal lavage was collected. Total RNA 
was extracted and microarray was carried out as described above. For parasite gene expression 
profiling, ToxoGeneChip array containing ~ 8000 features was used. Our results demonstrated 
that indeed, parasite genes were detectable. Ranking genes based on signal intensity value 
showed, genes involved in invasion (tubulin beta chain) and active replication of tachyzoite 
(MIC10, SRS52A) form to be highly expressed (Fig A2-4).  
Conclusions 
Unfortunately, limited conclusions could be made from this dataset. The initial increase 
in parasite concentration significantly changed the parasite ratio between strains. Based on this 
change, we are uncertain if gene expression profiles observed are due to parasite genetic 
background or parasite concentration. Further work is aimed to overcome this obstacle.  
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Type III (10^4) 
 
Rank 
 
Gene 
Signal 
Intensity 
1 Translationally-controlled tumor 
protein 17841 
2 MIC10 17719 
3 Histone Variant H3 16100 
4 Hypothetical protein 13650 
5 Elongation factor 1β 13627 
6 TgMLC1 0  13279 
7 Ribosomal protein L41 13171 
8 Tubulin beta chain, putative 12249 
9 Non-transmembrane antigen  10448 
10 Cytochrome oxidase I 10357 
11 Hypothetical protein 9624 
12 ER retention receptor, putative 8608 
13 ATP-dependent RNA helicase 8528 
14 SRS52A 8156 
15 Glycine-rich protein 2 7766 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2-4. In vivo increased parasite infection. CD-1 outbred mice were infected with 200 
tachyzoites of either Type I (GT1) or Type III (CTG), sacrificed, peritoneal lavage collected and 
total RNA isolated on Day 5. Biotinylated cRNA was hybridized to cDNA microarrays and 
signal intensity values were obtained. Only genes highly ranked were selected and normalized to 
GAPDH internal control. 
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Appendix III. Protocols  
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Challenge mice for In vivo competition assay  
1. Grow non-virulent T. gondii strain CTG and virulent GT1 in 2 (1 flask/ strain) T25 HFF cell 
culture until HFF cells are nearly lysed (normally in 48 hrs)  
2. Filter purify and harvest tachyzoites in 15-ml  centrifuge tube  
3. Make 1:10 dilution in D10 media. Determine parasite concentration using a hemacytometer  
4. Add 500 µl of GT1 (1x104) to 4mL of D10 * 
5. Add 500 µl of CTG (5x104) to 4.5mL D10/GT1 solution * 
6. Infect mice with 200 µl of GT1:CTG (1:5) via peritoneal injection  
7. Collect spleen, lung and peritoneal lavage @ days 4, 6 and 8  
8. For controls, infect 4 mice with GT1 and CTG  
a. Infect 2 mice with GT1 (200 tachys) only  
b. Infect 2 mice with CTG (1000 tachys) only  
c. On day 8 collect spleen, lung and peritoneal lavage from all mice  
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Detecting T. gondii in mouse tissue samples  
 
* All buffers, spin columns and collection tube are supplied by kit.  
1. Infect 4 mice with 200 toxo and harvest spleen and lung at day 7  
2. Weigh spleen and lung, freeze at -70C before use  
3. For spleen, adjust volume to .02 g/ml using PBS (total volume will be between 5 to 20 
ml). For lung, adjust volume to .01 g/ml using PBS. Take two aliquots (1
st
-200μl and 2nd 
-1mL) of tissue lysate, store at -20C before use.  
4. For controls (positive and negative), use tissue samples without T.gondii infection. 
5. Thaw tissue lysate (200μl). Spin at 12,000 rpm for 5 min. Remove supernatant and 
resuspend pellet in 180μl of Buffer ATL.  
6. Add 20μl of proteinase K. Mix by vortexing and incubate @ 56ºC until completely lysed. 
Invert periodically to facilitate digestion of tissue. Lysis usually occurs within 1-3 hrs. 
Treat positive controls by same procedure. 
7. For positive controls, harvest toxo (from four T25 flasks) and re-suspend in 1 ml of 
PBS. Make 2x 1:10 dilutions (100μl toxo + 900μl PBS) and count dilution 1:100. The 
concentration will be about 10
8
 toxo/ml. Make a series of 1:10 dilution to give 10
7
 to 10
4
 
toxo/ml. Spike the original and diluted toxo into 200μl of tissue lysate to make a series of 
concentration from10
7
 toxo /ml to 10
3
 toxo /ml. e.g.  
Spike 20 μl of 1x108 toxo/ml into 200μl lysate to make 1x107 toxo/ml 
Spike 20 μl of 1x107 toxo/ml into 200μl lysate to make 1x106 toxo/ml 
Spike 20 μl of 1x106 toxo/ml into 200μl lysate to make 1x105 toxo/ml 
Spike 20 μl of 1x105 toxo/ml into 200μl lysate to make 1x104 toxo/ml  
Spike 20 μl of 1x104 toxo/ml into 200μl lysate to make 1x103 toxo/ml  
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 * Pellet and resuspend as in step 5. Process as step 6 
8. Once complete lysis, vortex for 15s. Add 200μl Buffer AL to the sample. Mix thoroughly 
by vortexing. Then add 200μl ethanol (96-100%). Mix again thoroughly.  
9. Pipet the mixture into a DNeasy Mini spin column in a 2ml collection tube. Centrifuge at 
> 6000xg (8000 rpm) for 1min. Discard flow through and collection tube.  
10. Place the spin column in a new 2ml collection tube. Add 500μl Buffer AW1. Centrifuge 
for 2 min at > 6000xg. Discard flow through and collection tube.  
11. Place the spin column in a new 2ml collection tube. Add 500μl Buffer AW2. Centrifuge 
for 3 min at 20,000xg (14,000). Discard flow through and collection tube.  
12. Transfer the spin column to a new 1.5ml or 2ml microcentrifuge tube (not provided by 
kit) and add 200μl Buffer AE for elution. Incubate for 1 min at room temperature. 
Centrifuge for 1 min at > 6000xg.  
a. Repeat this step for maximum yield.  
 RTPCR: Cephaid Smartcycler 
ITSI primers 
ITS1-Fx: GAAGGGGCTCAATTTCTGG  
ITS1-Rx: TGTTCCTCAGATTTGTTGTTTGA 
 ITS1 probe was 5‟-/56-FAM/CGTGTCTCTGTTGGGATACTGATTTCCAGG/3BHQ-1/-3‟ 
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H20                                16.7μl           
MgCl2                             2.5μl 
dNTPs (2.5 μm)              2.5μl      
BSA                                1.0 μl 
For Primer (50 μM)        .15μl 
Rev Primer (50 μM)        .15μl 
Probe (50 μM)                 .3 μl 
Taq Polymerase               .2 μl 
 Total                               23.5 μl 
Add 1.5 μl cDNA each rxn.  
RT-PCR samples in smartcycler: 95ºC for 15 min, 94ºC for 10s, 55º for 30 s, 72º for 30 s, 
Repeat 40 cycles, 72ºC for 5min, Melting curve: 72-95ºC, 72ºC for 5 min.  
Once completed, analyze data from results table.  
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Isolation of total RNA from mice for Microarray Analysis 
Materials: Qiagen RNeasy Plus Mini Kit 
RNeasy Plus Mini Kit (50), Catalog no. 74134    
Number of preps      50 
gDNA Elimiantor Mini Spin Colums (uncolored) 
(each in a 2 ml Collection Tube)    50 
Rneasy Mini Spin columns (pink) 
(each in a 2ml Collection Tube)    50 
Collection Tubes (1.5ml)      50 
Collection Tubes (2ml)      50 
Buffer RLT Plus*       45 ml 
Buffer RW1*       45ml 
Buffer RPE+ (concentrate)     11ml 
RNase- Free Water       10ml 
70% ethanol 
Beta mercaptoethanol 
*Contains a guanidine salt. Not compatible with disinfectants containing bleach. See 
page 6 for safety information.  
+ Before using for the first time, add 4 volumes of ethanol (96-100%) as indicated on the 
bottle to obtain a working solution.  
Procedure:  
1. Grow parasite in T25 flask until nearly lysed (` 48 hr passage) 
2. Infect four CD1 outbred mice I.P. with 500 tachyzoites  
3. On day 5 collect peritoneal lavage in 5 ml of ice cold PBS 
4. In lab, pellet sample at 13,000 rpm for 10 min. Resuspend in 1 ml RNA later.. Store 
@ -20°C until use. 
 102 
 
Isolate total RNA:   
5. Spin down the cells at 12,000 rpm for 10 min, remove supernatant 
6. Resuspend in 1ml of PBS, take 200 µl to determine parasite load by Real-time PCR 
and genotype by PCR –RFLP (DNA will be extracted by Qiagen tissue and blood 
kit).  
a. For DNA extraction, Spin down cells at 12,000 rpm for 10 min.  
b. Resuspend in 1 ml PBS, pellet again at 12,000 rpm for 5 min 
c. Resuspend in 200 µl PBS, now samples are ready for extraction  
7. Take remaining (800 µl) spin down the cells at 12,000 rpm for 10 min, remove 
supernatant.  
8. Take aliquot of Buffer RLT Plus, add 10 µl beta- mercaptoethanol to 1ml RLT. 
Disrupt the cells by adding 600 µl Buffer RLT Plus. Pipet to mix. Ensure that no cell 
clumps are visible and cells are lysed.  
9. Transfer the lysate to a gDNA Eliminator spin column placed in a 2 ml collection 
tube. Centrifuge for 30 s at 12,000 rpm. Discard the column, and save the flow 
through.  
10. Add 1 volume (600 µl) of 70% ethanol to the flow through and mix well by pipetting. 
Do not centrifuge.  
11.  Transfer 600 µl of the sample to an RNeasy spin column placed in a 2 ml collection 
tube. Centrifuge for 15 s at 12,000 rpm. Discard the flow-through. Transfer the 
remaining 600 µl of samples to the spin column and centrifuge. Discard the flow 
through.  
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12. Add 700 µl Buffer RW1 to the RNeasy spin column. Close the lid and centrifuge for 
15 s at 12,000 rpm to wash the spin column membrane. Discard the flow through. Be 
sure to empty the collection tube completely. Reuse the collection tube.  
13. Add 500 µl Buffer RPE to the RNeasy spin column. Close the lid and centrifuge for 2 
min at 12, 000 rpm to wash the spin column membrane. Discard the flow through. 
Reuse the collection tube.  
14. Add 500 µl Buffer RPE to the RNeasy spin column. Close the lid and centrifuge for 2 
min at 12, 000 rpm to wash and dry the spin column membrane. Make sure no 
residual ethanol is carried over.  
15. Place the RNeasy spin column in a new 2 ml collection tube and centrifuge at 12,000 
rpm for 1 min to eliminate any possible carryover of Buffer RPE.  
16. Place the RNeasy spin column in a new 1.5 ml collection tube. Add 30 µl of RNase- 
free water directly to the spin column membrane. Close the lid and centrifuge at 
12,000 rpm for 1 min to elute the RNA.  
17. Add additional 20 µl of RNase- free water directly to the spin column membrane. 
Close the lid and centrifuge at 12,000 rpm for 1 min to elute the RNA.   
18. Store RNA at -70°C before use.  
 104 
Sonication/ Filtration of T. gondii Tachyzoites 
Purpose: To test sonication/ filtration method and its efficiency to rid host cell contamination for 
microarray analysis 
NOTE- test in vitro to confirm purification of parasite before in vivo work goes forth  
 
GAPDH Primers- Roussel et. Al, Vaccine 25 (2007) 2919-2929 
GAPDH-F: 5′-TGCACCACCAACTGCTTAG-3′ 19bp 
GAPDH-R: 5′-GGA TGC AGG GAT GAT GTT C-3′ 19bp 
5′-CAG AAG ACT GTG GAT GGC CCT-3 probe 21bp 
Product size – 177 bp 
ITSI primers 
ITS1-Fx: GAAGGGGCTCAATTTCTGG  
ITS1-Rx: TGTTCCTCAGATTTGTTGTTTGA 
 ITS1 probe was 5‟-/56-FAM/CGTGTCTCTGTTGGGATACTGATTTCCAGG/3BHQ-1/-3‟ 
Procedure: III parts  
I. Host cell detection 
1. Grow  (2) HFF T175 and (2) J774A.1 T175 flasks until confluent monolayer 
2. Remove media 
3. Dilute Trypsin 1:1 with sterile PBS 
4. Add 2 ml  of Trypsin/ PBS to each flask  
5. Incubate at 37ºC for 5min to detach cells from flask surface 
6. Determine host cell concentration using hemacytometer  
i. Make 1:100 dilution for counting  
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7. Aliquot 5 ml (2 x 106 conc.) cells into six 15ml tubes for each cell line 
i. Make total volume of 70 ml of 2 x 106 cells for each cell line tested 
8. Sonicate at 5 different settings to obtain optimal setting using: Sonicator Heat 
Systems ultrasonics inc. cell disrupter. Model W220F 
 make sure tubes stay on ice during sonication, produces heat* 
i. 10 sec @ setting 3 
ii. 5 sec @ setting 4 
iii. 10 sec @ setting 4  x 2 
iv. 5 sec @ setting 5 
v. 10 sec @ setting 5 
vi. Non sonicated cells serve as control 
8a. Pellet cells @ 1500rpm for 5 min 
8b. Resupsend in 5 ml PBS  
9. Remove 1 ml and extract DNA via Qiagen DNeasy Kit  
i. Elute in 100μl of elution buffer provided by kit 
10. Run Real Time PCR – according to Su lab protocol 
i. Target: GAPDH 
11. Determine host cell concentration 
i. Non sonicated cells will be determined as 1 and make a series of 1:10 
dilution for standard curve 
II. Parasite Detection 
1. Infect 2 HFF T25 HFF flasks w/ VEG until nearly lysed (~48hrs) 
2. Filter purify  
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3.  Harvest parasite in 50ml tube 
i. Pellet cells @ 1500g for 5 min 
ii. Resuspend in 1 ml PBS 
4. Determine parasite concentration using hemacytometer 
5. Aliquot 5 ml (2 x 106) parasite into six 15 ml tubes 
6. Follow sonication steps as described above in part I, step #8 
6a. Pellet @ 1500g x 5 min 
6b. Resuspend in 2 ml PBS 
7. Remove 1 ml and extract DNA via Qiagen DNeasy Kit 
i. Elute in 100μl of elution buffer provided by kit 
8. Run Real Time PCR- according to Su lab protocol 
i. Target: ITSI 
9. Determine parasite concentration 
III. Toxo/ Host cell detection 
1. Infect (4) T25 J77 A.1 flasks w/ VEG ~ 24-36 hrs 
2. Dilute Trypsin 1:1 with sterile PBS 
3. Add ~500μl of Trypsin/ PBS to each flask  
4. Incubate at 37ºC for 5min to detach cells from flask surface 
5. Determine host cell and parasite concentration using hemacytometer 
i. Make 1:100 dilution for counting  
ii. If counting is challenging, mount slide, fix in methanol and  Giemsa stain 
for differentiation 
6. Sonicate at same settings as in Part I, step #8  
 107 
7. Pellet @ 1000g x 5min 
8. Remove supernatant 
9. Resuspend in 5 ml PBS  
10. Filter purify and harvest parasite in 50ml tube (Do not filter control) 
i. Pellet @ 1500g x 5 min 
ii. Resuspend in 2 ml PBS  
11. Extract DNA according to Qiagen DNeasy Kit 
i. Elute in 100μl of elution buffer provided by kit 
12. Run Real Time PCR 
i. Targets: ITSI and GAPDH to quantify both parasite and host cell 
concentrations 
13. Determine optimal setting for destroying host cell but recovering the most 
parasite 
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2 Step qRT-PCR protocol: (DyNAmo Sybr Green Kit) 
 
Purpose: To obtain mRNA transcript levels of specific genes from mice infected w/ T. gondii.  
Materials:  
Primers as described above 
Finnzymes DyNAmo Sybr Green 2 step qRT- PCR kit 
Cat No. F430S (CDNA syn 20rxn, qPCR 80rxn) 
   F430L (cDNA syn 100 rxn, qPCR 400 rxns) 
Procedure:  
1. Infect mice CD-1 outbred mice with 500 tachys of Toxoplasma gondii 
2. On day 5 post infection, sacrifice mice and collect peritoneal lavage (in 5ml cold PBS), 
spleen and brain.  
3. Store tissue samples  in 1 ml RNAlater and store in -70 until use. 
4. In lab, pellet the cells in peritoneal lavage by centrifuging at 15000 rpm for 5 min @ 4C. 
Keep 2 ml and remove extra supernatant.  
5. Isolate total RNA according to protocol established by Rachel in accordance with Qiagen 
RNeasy Kit 
6.  Store in -70C until use.  
7. Quantify RNA samples before use to ensure accurate RNA concentrations.  
a. Normalize all samples to one concentration as not to have more than 1μg/ rxn.  
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I. cDNA synthesis- all reagents are supplied by kit 
H20*                                         x μl 
RT buffer                                10μl 
Random hexamer                      1μl 
primer set 
M-MuLV RNase RT                 2 μl 
RNA template*                         x μl 
Total                                        20 μl 
 values will vary based on initial concentration of RNA 
Run samples in mastercycler: 25ºC @ 10 min, 37ºC @ 30 min, 85ºC @ 5min, Hold @4C  
(If not using samples immediately, store @ -20ºC until use) 
II. qPCR 
H20                                  8.6 μl           
Master Mix                      10 μl 
For Primer (50 μM)         .2 μl 
Rev Primer (50 μM)        .2 μl 
 Total                               19 μl 
Add 1 μl cDNA from part I to each rxn.  
RT-PCR samples in smartcycler: 95ºC for 15 min, 94ºC for 10s, 55º for 30 s, 72º for 30 s, 
Repeat 40 cycles, 72ºC for 5min, Melting curve: 72-95ºC, 72ºC for 5 min.  
Once completed, analyze data from results table.  
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Cell Surface Staining 
Purpose: To quantify cell population of mice infected with Toxoplasma gondii .  
Materials: 96 well U-Bottom plate, Abs (Macrophage- CD11b/F18:FITC, DC‟s – CD11b:APC, 
Neutrophils-GR1:PE, Toxoplasma- Surface antigens: Secondary antibody (goat anti-mouse IgG-
PerCP; Santa Cruz biotechnology cat no. sc-45092 $96) 
Normal mouse serum 1/100 in PBS-0.1% BSA (FACS buffer) 
Experiment:  
1. Add 1x106 cells to designated wells of a 96 well U Bottom plate 
2. Centrifuge plate at 1500 rpm for 5 min at room temperature (~23ºC)  
3. Flick off supernatant, and vortex plate ( be sure that all cells are in suspension)  
4. Dilute normal mouse serum 1/100 in PBS-0.1% BSA (Sangster Lab) and add 100 μl to 
each sample. Pipette each sample up and down to ensure the cells and thoroughly 
resuspended. Change tips b/n each sample.  
5. Incubate plate on ice for 30 mins. 
6. Centrifuge plate at 1500 rpm for 5 min at room temperature (~23ºC) 
7. Flick off supernatant, and vortex plate ( make sure that all cells are in suspension)  
8. Dilute selected primary antibody 1/200 in PBS-.1%BSA (For Toxo; mouse serum from 
infected mice)  
9. Add 100 μl of primary Ab to appropriate wells. Pipette each sample up and down to 
ensure the cells are thoroughly resuspended. Change tips b/n each sample.  
10. Incubate plate on ice for 30 mins  
11. Centrifuge plate at 1500 rpm for 5 min at room temperature (~23ºC) 
12. Wash 2xs w/ PBS (vortex @ each wash to ensure complete cell suspension) 
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13. Dilute selected secondary Ab (goat anti-mouse IgM-PerCP) and Macrophage, DCs and 
neutrophil Abs to 1/200 and mix in cocktail. Add 100 μl to appropriate wells 
14. Add 100 μl of PBS-.1% BSA to unstained wells 
15. Wrap plate with foil and incubate on ice for 30 mins (Abs are light sensitive) 
16. Centrifuge plate at 1500 rpm for 5 min at room temperature (~23ºC) 
17. Flick off supernatant, and vortex plate ( make sure that all cells are in suspension)  
18. Resuspend cells in 100 μl of PBS -.1% BSA and transfer cells to appropriate tubes 
19. Add 600 μl of PBS -.1% BSA to each tube (If not analyzing on same day- Add 50 μl 
paraformaldehyde to fix cells 
20. Keep samples on ice and covered until ready to run using FACScan and Cellquest 
Software  
** Cells are viable ~48 hrs after staining to obtain accurate read, anything later discard 
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